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1Chapter 1: Introduction
Breast cancer and chemotherapy
Cancer is the second leading cause of death in the United States, with breast
cancer accounting for seven percent of the total.  The most common type of cancer in 
women, more than 217,000 new cases of breast cancer were diagnosed in 2004 and over 
40,000 individuals died from the disease.1  Based on these statistics it is clear that early 
detection methods and proper treatment must be improved upon.  
Breast cancer is typically treated with a combination of surgery, radiation, 
hormone therapy, and chemotherapy.  Chemotherapeutic agents are typically 
administered intravenously and travel throughout the body allowing them to reach the 
cancerous mass, whether it is in-situ or invasive.  This trademark of antineoplastic agents 
is a great advantage as it allows for the destruction of early metastases that, if using other 
forms of treatment would not be targeted. Because cancer cells have gained the ability to 
proliferate uncontrollably, it follows that the drugs have been designed to target rapidly 
dividing cells.  Unfortunately, this is also a weakness of chemotherapy as it targets 
otherwise healthy cells in the reproductive system and hair follicles, which must divide 
rapidly for normal function
Presently, more than sixty chemotherapy drugs are being used in the clinical 
setting, while the number of those undergoing clinical trials increases daily.2  In general, 
the drugs are designated as cell-cycle specific, meaning they kill cells only in a specific 
phase of the cell cycle, and non cell-cycle specific, allowing them to kill cells at any stage 
of the cycle.  The drugs are further divided into separate classes depending on their 
2specific mechanism of action.  All chemotherapy drugs work to slow and/or inhibit the 
growth and development of neoplastic cells, but exactly how they do so differs between 
the classes.  The antimetabolites and mitotic inhibitors, such as 5-fluorouracil and 
etoposide, are both cell cycle specific and work to impede nucleic acid synthesis to 
prohibit DNA replication in the S phase and to prevent cell division during mitosis, 
respectively.  On the other hand, alkylating agents, antitumor antibiotics and nitrosureas 
are all non cell-cycle specific.  Alkylating agents, such as melphalan bind DNA to 
prevent its replication and transcription, while the nitrosureas, which include the drug 
carmustine, block enzymes that function in DNA repair.  The antitumor antibiotics work 
in several ways including inhibition of nucleic acid synthesis, blocking of enzymes 
required for cell division and by changing cell membranes.  Drugs that fall into this class 
are either natural products, such as adriamycin, or are synthetic, like mitoxantrone.  
Improved cancer treatment results when the drugs are used in a combination that is often 
tailor designed on a case-by-case basis.  In this way, chemotherapy can be advantageous 
for some time.  Unfortunately however, chemotherapy often fails as a result of multi-drug 
resistance.
Drug resistance and its known mechanisms
Multi-drug resistance is the most challenging problem in the successful treatment 
of cancer and is the main reason why chemotherapy fails.3  When a tumor does not 
respond to treatment, namely chemotherapy, it is said to be drug-resistant.  Drug 
resistance is classified as either intrinsic or acquired.4  Intrinsic resistance results when 
cancerous cells are unresponsive to the first round of chemotherapeutic(s) they are 
exposed to.  Acquired resistance results when small populations of cells were not killed 
3after initial exposure to chemotherapy and thus proliferate with genetic alterations 
conferring this resistance to later populations.5  Multi-drug resistance is observed in both 
intrinsic and acquired resistance.  In this phenomenon, if a tumor metastasizes or comes 
back after remission, the cancerous cells are not only resistant to the drugs used 
originally, but are also resistant to a wide array of drugs that are not necessarily similar in 
their chemical structure, mechanism or cellular target.6  As a result of multi-drug 
resistance, chemotherapy is often unsuccessful.   
Although multi- drug resistance has been studied for nearly four decades it has yet 
to be fully understood.  To date, a handful of mechanisms responsible for drug resistance 
have been determined, including changes in drug accumulation and detoxification, DNA 
repair mechanisms and alterations along the apoptotic pathway.7  These mechanisms, 
which are illustrated in Figure 1, can be separated into three general classes; those that act 
upstream of the molecular target, those that act at the molecular target and those that act 
downstream of the target.  While some of these mechanisms have been studied 
extensively, others are still not well understood.  Furthermore, not all resistance can be 
explained by the known mechanisms, thus it stands that additional mechanisms of 
resistance have yet to be determined.  In order to improve current clinical treatment and 
to develop more effective chemotherapeutic agents, it is imperative that more insight be 
gained into the mechanisms of drug resistance.  
The efflux of chemotherapy drugs out of cancer cells through adenosine 
triphosphate (ATP)-dependent pumps is the most well characterized model of drug 
resistance.  The ATP binding cassette family comprises 48 proteins, ten of which have
4Figure 1.  Known mechanisms of drug resistance.  
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5been shown to confer drug resistance in cancer cells.8  In this family, the energy released 
from ATP hydrolysis at one of two ATP binding domains drives the efflux of drugs from 
the cytosol inside a cell to the outer extracellular matrix.6,8,9  In this way, drugs do not 
accumulate in cancer cells and cannot produce their typical chemotherapeutic effects.    
P-glycoprotein (Pgp) was the first member of this family shown to confer drug resistance.  
A product of the MDR1 gene, Pgp is a 170-kDa protein that can detect and expel a 
variety of drugs, including antitumor antibiotics and mitotic inhibitors.  When a drug 
binds Pgp it activates the first ATP binding cassette to hydrolyze ATP, which in turn 
causes a conformational change in the protein forcing it to release the drug.  ATP 
hydrolysis at the second binding domain allows Pgp to return to its natural conformation 
so that it can bind another drug molecule.4    Resistance caused by Pgp is detrimental; 
cells with intrinsic resistance to anticancer drugs conferred upon them by Pgp will induce 
the expression of high numbers of Pgp pumps once exposed to that same drug.  In turn, 
induction of Pgp then works to reduce the intracellular accumulation of the drug, which 
can encourage other mechanisms of drug resistance to develop.8 
 Besides Pgp, nine other ATP binding cassette family members that confer drug 
resistance on cancer cells have been identified, including the breast cancer resistance 
protein, which has been show to be over expressed in cells treated with anthracycline 
antibiotics.9,10  A second mechanism of resistance, decrease of drug influx into a cell is 
not understood nearly as well.  It has been shown that cells can gain resistance to drugs 
that enter the cytosol either through receptor-mediated transport or through endocytosis.  
Resistance in the former case occurs when mutations cause failure of the receptors to 
function properly, while in the latter, endocytosis is somehow defective.4  Drug resistance 
6can also be gained through an increase in drug-detoxification.11,12  In this way, enzymes 
such as Cytochrome p450 reductase and glutahione-S-transferase are responsible for the 
inactivation and excretion of drugs so that they cannot reach their cellular target.  
Deoxyribonucleic acid (DNA) is the cellular target for most chemotherapeutic 
drugs, with the premise that damage to this molecule should prevent cells from dividing 
uncontrollably.  Drug resistance at the DNA level has developed, however, as cancer 
cells can increase the expression of certain proteins to repair damage and decrease the 
expression of others to tolerate the damage that drugs impart on them.13,14  An increase in 
DNA repair allows the cancer cells to survive, while tolerance of the damage leads to 
acquired resistance at a later stage in treatment as it increases the mutation rate 
throughout the genome.  Drug-resistance arising at this point represents a key failure in 
traditional chemotherapy agents; they work indirectly by targeting DNA rather than the 
apoptotic pathway.  
Current understanding is that chemotherapeutic agents kill cells via apoptosis not 
by DNA damage.15,16  Because traditional drugs have not been designed to target the 
apoptotic pathway, they work to kill cells indirectly, which has several drawbacks.  First, 
cancer cells that survive after the drug has reached its “target,” or DNA, do so because 
they have developed alterations in their apoptotic pathway, including the modified 
expression of many proteins that both promote and prevent programmed cell death.17
This in turn ensures that the next generation of cells will be resistant to that particular 
drug.  It also guarantees multi-drug resistance as it has been determined that most drugs 
kill cells by activating the apoptotic pathway, which was disabled after treatment with the 
original drug.    
7Although it is clear that drug resistance is a major problem in cancer and other 
long-term therapy, the mechanisms behind it are not clear.  What is known is that drug-
resistance is multifactorial; there is likely more than one type of mechanism working in a 
single tumor at any given time.18  This reflects the fact that within a tumor, the individual 
cells themselves are heterogeneous in their genome and proteome.9  The goal of drug 
resistance research is to improve patient outcomes by developing multiple strategies to 
overcome and prevent drug resistance.19,20  In order to achieve this goal it is necessary to 
better understand the underlying mechanisms of resistance.
Drug resistance is multi-factorial; therefore no single protein will be responsible 
for all resistance.  Furthermore, proteins work in tandem to confer and promote 
resistance.21,22  Because many proteins are involved in drug resistance, it is advantageous 
to use experimental strategies that observe changes in the protein abundance profiles of a 
large number of proteins at once.  A proteomic analysis provides the most direct and 
robust approach.  
Mitochondria
Together, rough human genome sequence information contained in public 
databases and advances in mass spectrometry have facilitated the emergence of 
proteomics as a tool for large-scale protein analysis.  Due to the complexity of human 
cells, it is advantageous to study only a particular cell subset, such as an organelle.23  In 
this study, a mitochondrial fraction has been used for a proteomic analysis to interrogate 
differences in the protein profiles between a drug susceptible and drug resistant human 
MCF-7 breast cancer cell lines.  
Mitochondria are dynamic organelles that play key roles in many cellular
8processes, including apoptosis.  A cell can undergo apoptosis by means of the extrinsic or 
intrinsic pathway, both of which can converge at the mitochondria, as seen in Figure 2.24 
The extrinsic pathway is initiated when death activators such as tumor necrosis factor and 
the fas ligand bind transmembrane receptors to recruit FADD and activate the caspase 
cascade.  The intrinsic pathway is stimulated by stress factors including DNA damage 
that results from chemotherapy.  A hallmark of the intrinsic pathway is permeabilization 
of the inner and outer mitochondrial membranes by members of the Bcl-2 family of 
proteins.25,26,27  This permeabilization is critical, as it leads to the release of proteins such 
as cytochrome c and apoptosis inducing factor from the inner membrane space into the 
cytosol.28,29 Once in the cytosol, these proteins activate caspases, the family of proteins 
responsible for the morphological changes exhibited by apoptotic cells.30,31
As a result of the central role that mitochondria play in mediating apoptosis, the 
organelle is now the direct target of several experimental anticancer treatments designed 
to overcome apoptosis related resistance.  The experimental drug Lonidamine, currently 
in phase III clinical trials for breast cancer targets the permeability transition pore, a 
complex that spans the mitochondrial membranes and has been shown to be directly 
involved in apoptosis.32,33  In addition, mitochondrial DNA, which encodes thirteen 
proteins, has potential therapeutic implications as mutations in the genome are reported in 
most cancers, including breast, and are believed to be another mechanism of 
chemoresistance.34,35  Finally, the nuclear gene transcript, Mm-trag, which localizes to 
mitochondria is associated with taxol and adriamycin resistance in various cancer cell 
lines.36  Collectively, these observations provide evidence that mitochondria are 
intimately involved in drug resistance and support the rationale that the identification of
9Figure 2.  Extrinsic and intrinsic pathways of apoptosis
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proteins with altered abundances and structures in this organelle is vital to overcoming 
the problem.  
MCF-7 cells as a model system
A comparative proteomic analysis has been performed between a parental, drug-
susceptible MCF-7 breast cancer cell line and the MCF-7 cell lines that have been 
selected for resistance to adriamycin in the presence of verapamil and for mitoxantrone.  
The MCF-7 breast cancer cell line was established in 1970 from the pleural effusion of a 
patient with metastatic breast cancer.37  This cell line is a prominent model for studying 
estrogen-receptor positive breast cancer, as it has retained qualities of mammary 
epithelial cells and has also proven to be very stable.38  Because of this stability, multiple 
resistant lines have been derived from the original MCF-7 cell line, making it the most 
the most widely used breast cancer model to study drug resistance in-vitro.39
Professor Douglas Ross at the University of Maryland Medical School established 
the first MCF-7 cell line resistant to adriamycin in the presence of verapamil.  The 
parental MCF-7 cells were subjected to increasing step-wise concentrations of 
adriamycin and verapamil resulting in a line that is 900-fold resistant to adriamycin.10
Drug-resistance in this line cannot be attributed to over expression of P-glycoprotein.40  It 
has been shown that the breast cancer resistance protein is over expressed in this line, 
however further mechanisms of resistance are hypothesized.41,42,43
Adriamycin is a natural anthracycline antibiotic that is used to treat a variety of 
cancers.  Shown in Figure 3, adriamycin is a cell cycle specific inhibitor that targets the S 
phase.  The cytoxicity of adriamycin is two-fold.  At complex I of the electron transport 
chain in mitochondria, adriamycin is reduced by one electron to its semi-quinone form.44
11
Figure 3.  Chemical structure of adriamycin.
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The semi-quinone can then react with oxygen or hydrogen peroxide to produce reactive 
oxygen species.45  In turn, production of these free radicals generates oxidative damage to 
the cells so that apoptosis is initiated.46 In its second mechanism of action, adriamycin 
intercalates along the DNA helix where it interacts with topoisomerase II and causes 
double strand breaks in the nucleic acid so that DNA synthesis is prevented.44,47   
The chemical structure of verapamil is shown in Figure 4.  Verapamil is a small 
hydrophobic calcium channel blocker that that works as competitive inhibitor of Pgp to 
compete with all of its possible substrates, including adriamycin.9  It has been determined 
that an MCF-7 cell line selected for resistance to adriamycin alone produced a cell line 
with genetic and proteomic phenotypes distinct from those of the parental MCF-7 cell 
line.48,49  Furthermore, that cell line is now categorized as the ovarian cancer cell line, 
OVCAR-8.  Thus, in the MCF-7 cell line selected for resistance to adriamycin in the 
presence of verapamil, the Pgp inhibitor does not serve to overcome drug-resistance.  
Rather, the presence of verapamil during selection of this line ensures that it is a direct 
sub line of the MCF-7 cell line established in 1970.
As previously described, adriamycin localizes to mitochondria where it is reduced 
to a semi-quinone that can lead to the production of free radicals.  This largely 
contributes to the widespread use of adriamycin as an anticancer agent but also limits 
dosage, as the generation of reactive oxygen species results in irreversible cardiac 
damage.50   It has been shown that the increased expression of the mitochondrial protein, 
peroxiredoxin 3, can protect cancer cells against anthracycline induced apoptosis, 
however this has yet to be demonstrated with adriamycin.51  In addition to its localization 
at the electron transport chain, it has been shown that adriamycin interacts with
13
Figure 4.  Chemical structure of verapamil.
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cardiolipin, a lipid of the inner mitochondrial membrane.52  Adriamycin can also inhibit 
mitochondrial enzymes such as succinate dehydrogenase.53  Finally, in leukemia cells 
resistant to adriamycin, mitochondrial modifications have been reported.54  Whether such 
actions play a role in drug resistance is not yet clear, but together the data clearly support 
the use of the MCF-7 cell line selected for resistance to adriamycin in the presence of 
verapamil for the comparative analysis.  
The second cell line that has been used to study the role of mitochondria is that 
resistant to mitoxantrone.  This cell line was selected at the National Institutes of Health 
in the laboratory of Dr. Ken Cowan by increasing the concentration of mitoxantrone to 
which the MCF-7 cells were exposed.  The resultant cell line is 4000-fold resistant to 
mitoxantrone.55  A known mechanism that contributes to resistance is enhanced drug 
efflux due to the increased expression of the breast cancer resistance protein located in 
the plasma membrane.56,57
Mitoxantrone is a synthetic anthracenedione antibiotic.  The structure of the drug 
is shown in Figure 5.  It was designed to intercalate and bind DNA to cause single and/or 
double strand breaks and inter/intra-strand cross-linking, respectively.58  Also, 
mitoxantrone inhibits the activity of topoisomerase II to result in double strand breaks in 
DNA.  Collectively, the mechanisms result in the inhibition of DNA synthesis and repair.  
Drug resistance in this cell line is due in part to increased drug efflux but other 
mechanisms are likely.  It is worth studying the potential role that mitochondria may play 
in resistance for several reasons.  First, mitoxantrone toxicity is dependent on a fully 
functional electron transport chain.59  Second, mitoxantrone damages mitochondria, 
including disruption of the semi-permeability of the inner mitochondrial membrane and
15
Figure 5.  Chemical structure of mitoxantrone.
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the uncoupling of oxidative phosphorylation.60  Although this does not necessarily 
indicate a direct link between mitochondria and chemoresistance to mitoxantrone, the 
association between the drug and proteins within this organelle is apparent and should be 
explored.  This study will allow for the comparison of protein changes in cells resistant to 
adriamycin and mitoxantrone, both of which are used clinically against breast cancer.
Proteomics and comparative proteomics
Proteomics is the study of the proteome, or protein complement of the genome.  
After the human genome project was completed in 2000 it became apparent that genetic 
information is not sufficient to predict the biological function of proteins.  There are over 
20,000 human genes, but the number of estimated proteins is much greater than 100,000 
as a result of alternative splicing and post-translational modifications, the latter of which 
often determines the function of a protein and its expression status.61  Also, there is 
unreliable correlation between the levels of messenger RNA transcripts and the predicted
amount of protein.62  Thus, from the gene sequence alone it is impossible to predict if a 
protein will be expressed, which isform, and when at a given time in a particular cell 
state.   
The development of proteomics as a tool for the large-scale analysis of proteins in 
a single study was facilitated by the availability of rough human gene sequences publicly 
available and by advances in mass spectrometry that have allowed for rapid analyses with
increased sensitivity.63   Initially the main focus of proteomics was to identify every 
protein in a given cell type.  More recently however, it has become apparent that 
proteomics has widespread applications including comparison of disease states and 
17
characterization of protein-protein interactions to elucidate the components of protein 
complexes, signaling pathways and metabolic networks.64
A comparative proteomic analysis provides a quantitative comparison of 
abundances of proteins in two different states, such as disease versus normal or responses 
to the presence and absence of environmental stimuli.  The value of comparative 
proteomics cannot be underestimated.  Determination of protein changes in a cell in 
response to disease may decipher how disease occurs at the molecular level.65  In 
addition, the identification of biomarkers will allow for early detection and progression of 
diseases like cancer and allow for the development of novel therapies directed at those 
proteins.66,67
Two-dimensional gel electrophoresis
The first stage of most proteomic analyses is to reduce sample complexity by 
isolating a cell fraction of interest, such as an organelle.  Proteins are then solubilzed and 
separated, usually by 2-dimensional gel electrophoresis (2D-GE) and identified by mass 
spectrometry combined with bioinformatics.  Using 2D-GE one can separate complex 
mixtures and successfully resolve up to 1000 proteins on a single gel.61  The resultant gel 
map of intact proteins can be used to determine changes in protein abundances and the 
existence of post-translational modifications.68  These changes can be observed through 
manual inspection and quantified with the assistance of computer software.  
Two-dimensional gel electrophoresis separates proteins by isoelectric point on an 
immobilized pH gradient gel (IPG) strip in the first dimension and according to 
molecular weight by sodium dodecyl sulfate electrophoresis in the second.69  Since its 
conception in the 1970’s, 2D-GE has been improved upon in many ways, including the 
18
development of immobilized IPG strips.  This innovation, whereby the pH gradient is 
fixed within the acrylamide matrix of the gel, has markedly increased the reproducibility 
and resolution of conventional 2-D gels and has simplified the procedure, making it a 
robust method for proteomics work.62,68  Following protein separation, the gels are 
stained to reveal the proteins, which can be visualized as individual spots.  To identify the 
proteins, spots of interest are excised from the gel and subjected to an in-gel proteolytic 
digestion to produce peptides that can be recovered from the gel and analyzed by mass 
spectrometry.  Upon recovery, the peptides are identified by peptide mass fingerprinting 
or microsequencing, and the parent protein is identified from various databases.  An 
overview of the analysis is presented in Figure 6.  
Mass spectrometry
Mass spectrometry is a powerful analytical technique that determines the mass of 
an ion based on its mass to charge (m/z) ratio.  A mass spectrometer consists of three 
parts; the ionization source, a mass analyzer and a detector.  For analysis, sample 
molecules must be charged and must be airborne.  The ionization source generates ions.  
The ions are then directed to the mass analyzer where they are separated by their m/z 
ratio.  Finally, the ions are sent to the detector, which detects the arrival of ions at each 
m/z value and converts them into an electric signal.  Mass spectrometers vary in their 
type of ion source and mass analyzer, which ultimately dictate the instrument of choice 
for a particular need.  
Although mass spectrometry has been around for nearly a century, its application 
to biological macromolecules was limited until nearly fifteen years ago when two 
ionization sources, matrix-assisted laser desorption ionzation (MALDI) and electrospray
19
Figure 6.  Schematic of comparative analysis.
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ionization (ESI) were introduced.  Prior to the development of MADLI and ESI, it was 
difficult to generate ions from nonvolatile molecules, such as proteins and peptides.  The 
advent of these methods allowed for “soft” ionization, meaning fragmentation is 
minimized, a characteristic that is necessary for protein identification.  These methods 
revolutionized biological research and are often regarded as the most significant 
breakthrough in proteomics.61
Two separate groups introduced MALDI almost simultaneously in 1988.70,71  A 
schematic of MALDI is shown in Figure 7.  As the name implies, ionization requires co-
crystallization of the sample analyte with an organic, aromatic matrix.  Both vaporization 
and ionization occur when a laser strikes the matrix, causing its crystals to absorb the 
energy from the laser.72,73  Absorption of the lasers energy causes the matrix crystals to 
heat and expand so that sample analyte becomes airborne in a plume.  Ions are generated 
from a gas-phase proton transfer between the excited matrix and analyte molecules.  
Fragmentation of the sample is minimized because the matrix absorbs most of the energy 
from the laser itself, thereby protecting the sample. Once formed, the ions, which are 
typically singly charged, enter a vacuum and are directed to the mass analyzer.  
A time-of-flight (TOF) analyzer determines the m/z ratio of ions by measuring the 
time it takes for the ions to move to the detector.  In a mixture of peptides generated by 
trypsin digestion, each ion will have a different mass.  Once in the analyzer, the same 
amount of energy will be applied to the group of ions, which are then accelerated towards 
the detector.  Each ion will reach the detector at a different time; the lighter the ion, the 
more quickly it will reach the detector and vice versa.  The time it takes each ion to reach 
the detector is directly proportional to the m/z ratio of an individual ion and can be used
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Figure 7.  Schematic of matrix-assisted laser desorption ionization (MALDI). 
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to determine the mass of the ion following the formula, m/z = 2eEls(t/ld)2, where e is the 
electronic charge, E is the extraction field, ls is the length of the source, ld is the length of 
the field drift region, and t is the time of flight of the ion. 
 John Fenn combined electrospray ionization with mass spectrometry in the 
1980’s.74,75  In this method, which is illustrated in Figure 8, samples are volatilized and 
ionized directly from a liquid solution of sample analyte and solvent.  The liquid mixture 
is sprayed from the tip of a needle towards the orifice of the mass spectrometer across a 
strong electric field.  This serves to generate a fine mist of charged droplets.76  Dry gas 
and/or heat is applied to the droplets at atmospheric pressure to evaporate the solvent, 
which produces gaseous charged ions.  Unlike MALDI, where the ions are most often 
singly charged, ESI produces multiply charged ions usually as a result of multiple 
protonations or deprotonations.74  This characteristic of ESI is advantageous as it allows 
for the masses of large molecules to be determined even if the mass range of the analyzer 
is small.  Another advantage of ESI is that it can be readily interfaced to liquid separation 
techniques such as HPLC.  ESI was improved upon through the advent of 
nanoelectrospray, which utilizes a smaller needle that is positioned closer to the orifice, 
to result in higher sensitivity.77    
It is commonplace that ESI is combined with a triple quadrapole mass analyzer or 
quadrapole TOF (ESI-qTOF) analyzer to perform tandem mass spectrometry (MS/MS).  
In the former, three quadrapoles are aligned in a row while in the latter, a TOF analyzer 
replaces the last quadropole.  One use of MS/MS is to sequence peptides.  To do so, the 
ions must first be generated and then selected for activation and fragmentation.  In the 
first quadrapole, precursor ions are selected.  The second quadrapole houses gas for
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Figure 8.  Schematic of electrospray ionization (ESI).
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collisional activation, while the third analyzes product ions from the selected precursors.   
Protein identification and bioinformatics
Protein identification using mass spectrometry combined with bioinformatics is 
achieved by either peptide mass fingerprinting or peptide microsequencincg.  To identify 
a protein by peptide mass fingerprinting, a peptide mixture is generated from the 
proteolytic digestion of a purified protein.  A mass spectrum is then produced of all the 
observed molecular masses of the ions, each corresponding to a single peptide.  Using a 
search engine such as Mascot, this list of peptides is compared to the theoretical digest 
generated in silico from all proteins in a selected database, such as SwissProt.78  Search 
engines allow the user to change certain variables that he/she has controlled for, including 
taxonomy, proteolytic enzyme used and number of allowable missed cleavages.  Using its 
own algorithm, the search engine creates a set of candidate proteins with which the 
measured peptides correlate, then ranks and scores the proteins based on how closely they 
meet the users selected criteria.  Positive protein identification usually requires that five 
to eight peptides be matched for a 50 kDa protein and even more for larger proteins.79
There are several limitations to peptide mass fingerprinting.  First, this method cannot be 
used to identify mixtures of proteins.  Second, small proteins are troublesome to identify, 
as they do not yield many peptide fragments.  Also, occasionally, two peptides with the 
same mass but different amino acid sequences occur which without sequence information 
cannot be distinguished.  
Peptide fragmentation, or microsequencing, on the other hand, can be used for 
protein mixtures as it does provide sequence information, thus making it much more 
specific than peptide mass fingerprinting.  In this method, peptides are fragmented by 
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collision-induced dissociation.  An ion of interest is selected and subjected to 
fragmentation to generate a mass spectrum from which part of its amino acid sequence 
can be interpreted.  Like peptide mass fingerprinting, protein identification based on 
microsequencing is facilitated through bioinformatics.  Usually, the partial sequence 
information is combined with mass information and submitted to a search engine.78,80
The search engine then returns the ranked and scored proteins from which that peptide 
may have originated. Using sequence tags from more than one peptide decreases the 
likelihood that the protein identification is erroneous.  It is also possible to submit entire 
MS/MS spectra combined with mass information to a search engine.73  In this case, the 
engine generates theoretical spectra from peptides of that mass and determines the best 
match. 
Collision induced dissociation can be done on a variety of instruments including 
ESI-qTOF mass spectrometers.  In this instrument, which is illustrated in Figure 9, there 
are two quadropole cells, Q0 and Q1, a collision cell, Q2 and a TOF-reflectron analyzer.  
A single mass spectrometric analysis is done to determine what ions are present in the 
sample mixture.  In this precursor ion scan, Q0 and Q1 serve as an ion guide whereby all 
ions are pulsed into the TOF analyzer.  To fragment the ions of interest, a product ion 
scan or MS/MS analysis is run.  In this mode, Q0 serves as the ion guide while Q1 serves 
as a mass filter; it only accelerates the ion of interest into the collision cell.  Here, 
nitrogen gas is transmitted into the cell where it repeatedly collides with the ion to 
produce fragment ions that are then accelerated to the analyzer and fragment ion spectra 
recorded.  This analysis usually produces two types of product ions by cleavages at the 
peptide bonds, designated as b and y ions.  If the charge from the parent ion is retained on
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Figure 9.  Schematic of a quadropole time of flight mass spectrometer
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the amino terminus of the fragment ion, a ‘b’ ion is produced.  Conversely, if the charge 
is retained at the carboxy terminus, the detectable fragment is a ‘y’.  This is illustrated in 
Figure 10.  Amino acid sequences generated from collision induced dissociation are 
relatively simple to interpret, as the mass difference between two consecutive b or y-ions 
is equal to the mass of an amino acid.
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Figure 10.  Fragmentation of a peptide to generate b and y-ions.
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Hypothesis and objectives
Drug-resistance due to chemotherapy is the most common cause of treatment 
failure in cancer.  It is important to understand the mechanisms of drug resistance in order 
to improve patient outcome and develop enhanced therapies.  The ability of cancer cells 
to evade apoptosis is one way in which drug-resistance develops.  Mitochondria play a 
central role in mediating apoptosis; many proteins associated with the organelle can 
promote or inhibit apoptosis.  Also, many chemotherapy drugs associate intimately with 
mitochondria.  Mitochondrial proteins may play an important role in the development of 
drug resistance.  We hypothesize that the identification and characterization of 
mitochondrial proteins with altered abundances in drug resistant cancer cells will help 
decipher the mechanisms drug resistance.
The primary objective of this research is to contribute to the understanding of 
mechanisms of drug-resistance conferred by mitochondrial proteins.  To do so I have:
1. Developed a reproducible method to isolate, purify and obtain the soluble proteins 
from MCF-7 cancer cell mitochondria
2. Created a proteomic gel map of the soluble mitochondrial proteins from MCF-7 
cancer cells
3. Identified proteins with altered abundances between a drug-susceptible MCF-7 
cancer cell line and MCF-7 cell lines selected for resistance to adriamycin in the 
presence of verapamil and for mitoxantrone
4. Considered mechanisms of drug resistance based on the function of altered 
mitochondrial proteins 
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Chapter 2: Materials and Methods
Materials
Dr. Ken Cowan at the National Institutes of Health generously provided the parent and 
mitoxantrone resistant MCF-7 human breast cancer cell lines.12,81  Dr. Douglas Ross at 
the University of Maryland medical school graciously provided the MCF-7 breast cancer 
cell line selected for resistance to adriamycin in the presence of verapamil.10   The  two-
dimensional quantitation kit, two-dimensional clean up kit and Percoll were obtained 
from Amersham Biosciences, which is now part of GE Healthcare (Piscataway, New 
Jersey).  The protein isoelectric focusing cell, immobilized pH gradient (IPG) strips (17 
cm, pH 3-10), IPG buffer, Protean II ready gels (8-16% Tris-HCl precast gel 
193x183x1.0mm IPG comb) and BioSafe Coommassie blue stain were obtained from 
Bio-Rad (Hercules, California).  Sequence grade, modified porcine trypsin was obtained 
from Promega Corporation (Madison, Wisconsin).  Phosphate buffered saline (PBS), 
urea, thiourea, 3-[(3-cholamidopropyl) dimethylammonio]-1-propanesulfonate 
(CHAPS), dithiothreitol (DTT), iodoacetamide, ethylene glycol-bis (-aminoethyl ether)-
tetraacetic acid (EGTA), mannitol, sucrose, 4-morpholinepropanesulfonic acid (MOPS), 
calcium chloride, ammonium bicarbonate, sodium chloride, trifluoroacetic acid (TFA), 
Eagle’s minimal media (MEM), fetal bovine serum (FBS), cell culture grade trypsin, 
penicillin streptomycin antibiotic solution, Trizma base, sodium dodecylsulfate (SDS) 
and glycerol were obtained from Sigma Aldrich (St. Louis, Missouri).  
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MCF-7 cell culture and harvest
The drug susceptible MCF-7, adriamycin resistant and mitoxantrone resistant 
MCF-7 cell lines were cultured in house.  The cells were grown on 150 cm2 flasks 
(Corning Incorporated, Corning, New York) in MEM supplemented with 10% fetal 
bovine serum and 1% penicillin streptomycin antibiotic solution.  The cells were 
sustained in an incubator at a temperature of 37ºC with 5% carbon dioxide.  Once they 
reached confluence, the cells were harvested.  First, cells were washed with 25 mL of 10 
mM PBS.  Then, 5 mL of cell culture grade trypsin was added and the flasks returned to 
the incubator in order to dislodge the cells.  After several minutes (5 minutes for parent 
and mitoxantrone resistant cells, 10 minutes for the adriamycin resistant cells), 15 ml of 
MEM was added to hinder the trypsin.  Cells were washed from the flask and pelleted in 
a centrifuge at 500g for 5 minutes.  The cell pellet was washed two times with PBS, 
weighed and subjected to subcellular fractionation.  
Isolation and purification of mitochondria
Mitochondria were isolated through a combination of homogenization, 
differential centrifugation and density gradient purification.  All work was done on ice 
unless specified otherwise.  The cell pellet was suspended in mitochondria isolation 
buffer (MIB; 220 mM mannitol, 70 mM sucrose, 5 mM MOPS, pH 7.4 plus 2 mM 
EGTA) at a ratio of 1 g cell pellet to 10 mL MIB.82  The suspension was manually 
homogenized using 70 strokes in 4 mL aliquots in a 7 mL Tenbroeck tissue grinder 
(VWR International Incorporated, Bridgeport, New Jersey).  The homogenate was spun 
at 400g for 10 minutes to pellet the unbroken cells and nuclei.  The supernatant was 
transferred to a pre-weighed 50 mL centrifuge tube (Fisher Scientific, Pittsburgh, 
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Pennsylvania) and kept on ice. The procedure was repeated but the pellet suspended in 
half the quantity of MIB used originally, and homogenized with only 50 manual strokes.  
After a second spin at 400g for 10 minutes, the supernatant was combined with that 
obtained previously and spun at 7000g for 10 minutes to pellet the crude mitochondrial 
fraction.  
The crude mitochondria were weighed and suspended in a ratio 800 µl 
mitochondria purification buffer (MPB; 220 mM mannitol, 70 mM sucrose, 5 mM 
MOPS, pH 7.4) to 0.8 g crude mitochondria.  One milliliter of the suspension was layered 
over 14 ml of MPB and 6 mL of Percoll in a 50 mL thickwall polycarbonate centrifuge 
tube (Beckman Coulter, Palo Alto, California).  The sample was spun in a fixed angle 
rotor (Ti 70, Beckman Coulter) at 38,900 rotations per minute (rpm) in a preparative 
ultra-centrifuge (Beckman Coulter).  As seen in Figure 11, upon removal from the 
centrifuge, three layers could be distinguished, the bottom two of which contain 
mitochondria.  The top layer was removed to waste with a 1 mL pipette.  The bottom, 
dark yellow layers were collected into 4 separate centrifuge tubes in 5 mL aliquots, 
diluted 10 fold with MPB buffer and centrifuged at 7000g for 10 minutes to pellet the 
mitochondria.83  The purified mitochondria from each tube were combined into one pre-
weighed tube, washed twice with MPB buffer and weighed.      
Preparation of soluble proteins
Purified mitochondria were suspended in protein extraction buffer (PEB; 7M 
Urea, 2M thiourea, 4% Chaps, 65 mM DTT, and 2% IPG buffer) at a ratio of 0.1g 
mitochondria to 600 µl PEB.84  To rupture the mitochondria, the suspension was placed in 
a beaker of ice and subjected to six, five second bursts of probe sonication (Sigma 
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Figure 11.  Schematic of density gradient purification of mitochondria.  Layer 1 contains 
cellular debris and peroxisomes.  Layers 2 and 3 contain purified mitochondria.
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Layer 2
Layer 3
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Aldrich) with a one-minute rest in between.  Equal volumes of the sample were placed in 
15 mL ultra-clear centrifuge tubes (Beckman Coulter) and centrifuged in a swinging 
bucket rotor (SW 60, Beckman Coulter) at 28,000 rpm for one hour to separate the 
soluble and insoluble proteins.  The supernatant, or soluble protein fraction was collected 
and portioned into1 ml aliquots so that protein concentration could be determined.
The two-dimensional quantitation kit was used to measure protein concentration, 
as it is compatible with the high concentrations of chemicals in the PEB.  Two sample 
dilutions were made in triplicate for accuracy and reproducibility.  A series of bovine 
serum albumin dilutions; 0, 10, 20, 30, 40 and 50 µg/50µL were used to generate the 
standard curve.  Absorbance was read at 480 nm on a DU 530 life science UV/Vis 
spectrometer (Beckman Coulter).  Protein concentration was calculated based on 
absorbance and dilution fold.  The volume of mitochondrial protein extract required to 
run a single 2-D gel experiment, 300 µg, was placed in individual Eppendorf tubes, flash 
frozen with liquid nitrogen and stored in a -80ºC freezer.
Prior to 2-D gel electrophoresis the mitochondrial proteins were precipitated using 
the two-dimensional clean-up kit.  The mitochondrial extract contains salts and buffers 
that can interfere with protein separation in the first dimension of 2-D gel electrophoresis.  
Thus, the proteins must be separated from the contaminants for a successful gel 
experiment.  To do so, the two-dimensional clean-up kit was used to precipitate the 
mitochondrial proteins.  Generally, recovery was about 90%, which was compensated for 
by increasing the volume of sample that was used.  Following precipitation, the 
mitochondrial protein pellet was solubilized in 320 µl of rehydration buffer (7M urea, 2M 
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thiourea, 2% Chaps, 50mM DTT and 1% IPG buffer) and incubated on the bench top for 
1 hr at room temperature.
2-D gel electrophoresis and comparative gel analysis
For a single 2-D gel experiment, we required that 300 µg of mitochondrial 
proteins be used.  To begin the first dimension separation, the rehydration solution was 
pipetted onto the isoelectric focusing tray.  An electrode wick saturated with 6 µL of 
distilled water was placed over the electrode at the anode, while a second wick saturated 
with 6 µL of 15 mM DTT was placed at the cathode to facilitate focusing of basic 
proteins.85  A 17 cm IPG strip, pH 3-10 was placed gel side down and covered with 1.5 
mL of mineral oil to prevent it from burning.  The strip was rehydrated for 12 hours, after 
which proteins were focused for 60,000 V-hr.    
After completion of isoelectric focusing, the IPG strip was placed in 3.5 mL of 
equilibration buffer (0.375 M tris-HCl, pH 8.8, 6M urea, 20% glycerol, and 2% sodium 
dodecylsulfate (SDS)) containing 2% DTT followed by 2.5% iodoacetamide to reduce 
and alkylate the proteins, respectively.  Because it contained SDS, the equilibration 
buffer served to denature the proteins and also coated them with a negative charge.  Thus, 
the inherent shape and charge of each protein had no effect and the proteins were 
separated in the second dimension based only on their molecular weight.  The strip was 
placed on top of an 8-16% Tris-HCl precast gel and covered with agarose solution.  The 
gel was developed at 16 mA for 30 minutes followed by 24 mA for approximately 5hr.  
Once the second dimension was complete, the gel was removed from between two glass 
plates and rocked gently for 1 hour in 500 ml of, 45% methanol, 5% acetic acid and 50% 
distilled water, to fix the proteins.  After it was fixed, the gel was washed in water for 15 
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minutes and then stained overnight in Bio-safe colloidal Coomassie blue.  Lastly, the gels 
were destained with gentle rocking in several washes of water so that densitometric 
image analysis could be performed with little background interference.  
Two-dimensional gel images were visualized using a GS-800 calibrated 
densitometer (Bio-Rad) and its associated software.  The gel images were scanned into 
the computer and saved as TIFF files.  Image analysis was performed using Compugen 
Z3 software (Compugen Limited, Tel Aviv, Israel).  Each gel image was registered and 
the software measured the relative expression of each spot in the gel.  For comparative 
analysis, two gel images of choice were registered, layered on top of one another and the 
spots were matched after local adjustments had been made.  The difference in abundance 
between the same spot on two gels was calculated based on the quotient of their relative 
expression on each gel, and was displayed by the computer program.  For verification of 
the results, manual calculations were performed on each pair of spots.  In order to ensure 
that the changes in abundance were not a result of biological or manual variation, each 
cell line was harvested four separate times and at least two gels were run from each of the 
harvest.  As a minimum, the exemplary gel from each harvest, for each MCF-7 cell line, 
was used to complete the comparative analysis.  Figure 12 is a schematic representation 
of comparative image analysis using Compugen Z3 software.   
In-gel tryptic digestion and preparation of proteins
Peptides were analyzed to identify proteins of interest.  An in-gel trypsin 
digestion was performed on protein spots with some modifications on the method of 
Mann.86  All steps were done at room temperature except as noted otherwise.  Using a 
plastic pipette, the protein spot of interest was carefully excised from the gel.  The spot 
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Figure 12.  Schematic of comparative image analysis using Compugen Z3 software.
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was placed in a 1.5 mL Eppendorf tube (Brinkmann Instruments, Westbury, New York) 
and using a scalpel, cut into cubes approximately 1-mm3 in size.  Gel pieces were washed 
for 15 minutes in 50 µL of distilled water followed by 15 minutes in 50 µL of 50% 
acetonitrile.  The liquid was removed and replaced with 50 µL of acetonitrile for 3 
minutes to shrink the gel particles.  Once they shrunk, the acetonitrile was removed and 
50 µL of 0.1 M ammonium bicarbonate (NH4HCO3) solution was added to the tube.  
After 5 minutes, 50 µL of acetonitrile was added and the gel pieces were incubated for 15 
minutes at room temperature.  All liquid was then removed and the gel pieces were 
completely dried down in a vacuum centrifuge for 15 minutes.  Once dry, 50 µL of 
10mM DTT in 0.1M NH4HCO3 was added and the tubes were incubated at 56ºC in a 
water bath for 45 minutes to reduce the proteins.  Upon removal from the water bath, the 
tubes were placed on the bench top for 10 minutes so that they could cool to room 
temperature.  The liquid was removed, replaced with 50 µL of 55 mM iodoacetamide in 
0.1 M NH4HCO3 and placed in the dark for 30 minutes to alkylate the proteins.  Next, the 
liquid was removed and an additional wash step was done to ensure that no Coomassie 
blue remained in the gel pieces, as it presence would not be conducive to mass 
spectrometry analysis.  To begin the wash, 50 µL of 0.1 M NH4HCO3 was added to the 
gel for 5 minutes, followed by the addition of 50 µL of acetonitrile.  The liquid was 
removed and the gel pieces were completely dried down in a vacuum centrifuge for 15 
minutes.  To digest the proteins, 20 µL of digestion buffer (50 mM NH4HCO3, 5 mM 
CaCl2 and 12.5 ng/µL of sequence grade trypsin) was added to each tube, which was 
immediately placed on ice and incubated for 45 minutes.  Incubation at this stage ensured 
that the trypsin was taken up by the gel pieces.  After 45 minutes, the digestion solution 
39
was removed and replaced with 20 µL of, 50 mM NH4HCO3 and 5 mM CaCl2 solution 
and placed in a 37ºC water bath overnight for digestion to take place.  After digestion had 
finished the peptides needed to be eluted from the gel pieces.  To begin, 25 µL of 25 mM 
NH4HCO3 was added to each tube for 15 minutes to swell the gel pieces.  Next, 25 µL of 
acetonitrile was added for 15 minutes to shrink the gel pieces.  This cycle of swelling and 
shrinking served to push the peptides out of the gel pieces and into the supernatant, which 
was subsequently collected in a new Eppendorf tube.  The extraction process was 
repeated two times with 5% formic acid in place of ammonium bicarbonate and the 
combined supernatants were completely dried down in a vacuum centrifuge for 
approximately 45 to 60 minutes.
Once the peptides had dried down, they were desalted.  This step was imperative 
as salt hinders ionization, produces noise in spectra and can damage a mass spectrometer.  
To desalt peptides that originated from proteins that were more basic, of high molecular 
weight and/or were in high abundance, ZipTipC18 columns (Millipore, Billerca, 
Massachusettes) were used, while proteins that were smaller or less abundant were 
desalted on Omix Tip C18 columns (Varian, Lake Forest, California).  Both are reverse 
phase columns that utilized the same procedure.  To begin, the dried peptides were 
dissolved in 10 µL of 0.1% TFA in water.  The column was then equilibrated; it was 
attached to a pipette and 10 µL of wetting solution (50% acetonitrile) was drawn into the 
tip, two times, followed by two rounds of aspiration of equilibration solution (10 µL of 
0.1% TFA in water).  To bind peptides to the column, 10 µL of peptide extract was 
drawn into and dispensed from the tip ten times.  Bound peptides were then washed twice 
with equilibration solution.  Finally, desalted peptides were recovered from the column 
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when 4 µL of elution solution (0.1% TFA in 50% acetonitrile) was aspirated and 
dispensed from the tip ten times.  For MALDI-TOF mass spectrometry, one microliter of 
the peptide extract was placed in a separate tube to be used directly for analysis.  For 
electrospray, the extract was dried down in a vacuum centrifuge for 10 minutes and 
dissolved in 5 µL of electrospray solution (49% water, 49% methanol, 2% acetic acid).         
Mass spectrometry and protein identificaiton     
MALDI-TOF analyses were performed on an AXIMA-CFR instrument (Kratos 
Analytical, Chestnut Ridge, NewYork) on protein spots that were high in abundance.  A 
half microliter of peptide extract was placed on the sample plate, over which the same 
volume of matrix (50 mM alpha-hydroxycinnamic acid in 0.1% TFA/ 70% acetonitrile) 
solution was placed.  The analyte and matrix co-crystallized when dried at room 
temperature for approximately 20 minutes, after which time the plate was introduced into 
the mass spectrometer.  Following the manufacturer’s recommendation for protein 
identification by peptide mass fingerprinting, the instrument was set in reflectron mode, 
with laser power between 45 and 55, and a scan range of 1-4000 m/z units.  Spectra were 
generated by averaging 100 profiles, each of which was taken from a different area as the 
sample was advanced across the lasers focal point.  Those spectra, whose peak height to 
background noise ratio was greater than 2 to 1, were recorded in the Mascot search 
engine available at www.matrixscience.com, and submitted to the protein database 
SwissProt.  Mascot generates a list of tryptic peptide masses for each protein in the 
SwissProt database and compares the experimental list of masses with each theoretical 
list.  Mascot then ranks the proteins and returns a positive identification when the chance 
of a false-positive identification is less than one in twenty.  The identification was then 
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checked to see if the pI and molecular weight of the protein correspond to that of the 2D-
gel spot from which it was obtained.  Figure 13 illustrates the use of peptide mass 
fingerprinting to obtain an identification of the mitochondrial protein, prohibitin.   
Proteins that could not be identified by peptide mass fingerprinting and those that 
were less abundant, as determined by intensity of that spot on the 2-D gel map were 
examined by generating peptide sequence tags with tandem mass spectrometry.  In this 
study all MS/MS work was done by collision induced dissociation on an API QSTAR 
Pulsar Qq-TOF electrospray ionization instrument (Applied Biosystems, Foster City, 
California).  To introduce the sample, 1.5 µL of electrospray buffer solution containing 
the peptide mixture was loaded into a capillary tip (Protana Incorporated, Odense, 
Denmark) and placed in the nanospray source.  In order to determine what peptide 
molecular ions were present in the sample mixture, it was necessary to first run a 
precursor scan.  To do so, the spray voltage was set to 900 V and the MS scan range was 
set between 350-1000 m/z; only peptides whose m/z ratio fell within that range were 
allowed to pass through the Q1, or mass filter quadropole cell.  Once the MS spectrum 
had been produced, doubly charged peptides were manually chosen for fragmentation.  In 
the product ion scan, only the peptide of interest was isolated in Q1 and allowed to pass 
into the collision cell, Q2.  To induce fragmentation, a controlled amount of nitrogen gas 
was transmitted into the collision cell.  Typically ions whose m/z value was less than 600 
required collision energy in the range of 20 to 32, while the collision energy needed to 
fragment ions of a larger m/z value ranged between 32 and 45.  The fragmented ions 
were pulsed to the detector and an MS/MS spectrum was recorded.  Because CID spectra 
generally produce b and y-ions, a partial peptide sequence could be easily deduced, 
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Figure 13.  Identification of the mitochondrial protein prohibitin by peptide mass 
fingerprinting.  
Protein spot of 
interest
1     MAAKVFESIGKFGLALAVAGGVVNSALYNVDAGHRAVIFDRFRGVQDIVV
51   GEGTHFLIPWVQKPIIFDCRSRPRNVPVITGSKDLQNVNITLRILFRPVA
101 SQLPRIFTSIGEDYDERVLPSITTEILKSVVARFDAGELITQRELVSRQV
151 SDDLTERAATFGLILDDVSLTHLTFGKEFTEAVEAKQVAQQEAERARFVV
201 EKAEQQKKAAIISAEGDSKAAELIANSLATAGDGLIELRKLEAAEDIAYQ
251 LSRSRNITYLPAGQSVLLQLPQ
Mass List
1149.4
1185.4
1213.4
1396.5
1444.3
1606.3
1997.2
2118.2Protein identified as prohibitin with 40% sequence 
coverage
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most usually by calculating the mass differences between consecutive peaks.  Usually, 
sequence tags from two to five peptides were used for protein identification.  The 
sequence tags, masses of the peptides and masses on each side of the tag were submitted 
through Mascot using the BioExplore software program associated with the mass 
spectrometer, which interrogates the protein databases, SwissProt and NCBI (National 
Center for Biotechnology Information).  Again, the search engine (Mascot) returned a list 
of candidate proteins from which the sequence tags could have originated.  Mascot 
ranked the proteins and determined the identity to a 95% confidence level.  It follows that 
the identification was more reliable when an increased number of peptide sequence tags 
were matched to a single protein.  As with proteins identified by peptide mass 
fingerprinting, the pI and molecular weight of the candidate protein were checked against 
the location of that spot on the 2-D gel.  Figure 14 shows the identification of delta3,5-
delta2,4-dienoyl- CoA isomerase, a mitochondrial matrix protein, using tandem mass 
spectrometry.  
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Figure 14.  Identification of the mitochondrial protein, delta3,5-delta2,4-dienoyl-CoA 
isomerase by peptide microsequencing.
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4 sequence tags were used to identify the protein,
delta 3,5-delta 2,4-dienoyl-CoA isomerase
1 MAAGIVASRRLRDLLTRRLTGSNYPGLSISLRLTGSSAQEEASGVALGEA
51 PDHSYESLRVTSAQKHVLHVQLNRPNKRNAMNKVFWREMVECFNKISRDA
101 DCRAVVISGAGKMFTAGIDLMDMASDILQPKGDDVARISWYLRDIITRYQ
151     ETFNVIERCPKPVIAAVHGGCIGGGVDLVTACDIRYCAQDAFFQVKEVDV
201 GLAADVGTLERLPKVIGNQSLVNELAFTAHKMMADEALDSGLVSRVFPDK
251 EVMLDAALPLAPEISSKTTVLVQSTKVNLLYSRDHSVAESLNYVASWNMS
301 MLQTQDLVKSVQPTTENKELKTVTFSKL
Sequenced Peptides
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Chapter 3:  Results
Preparation of mitochondrial proteins
A reproducible method to isolate, purify and extract the soluble proteins from 
MCF-7 cancer cell mitochondria has been optimized.  At confluence, approximately 
6-8 x 106 cells were harvested from each of twenty 150 cm2 flasks.  Typically, between 
three and four grams of cell pellet was obtained.  From this, we were able to isolate a 
crude mitochondrial pellet and purified mitochondrial pellet that weighed one-half and 
one-tenth of the weight of the original cell pellet, respectively.  Following purification of 
the organelle, we were able to extract one milligram of soluble mitochondrial proteins.
Protein identification and evaluation of purification method
The soluble mitochondrial proteins were separated by 2D-GE.  After the gel 
images were recorded, protein spots of interest were excised and subjected to in-gel 
digestion with trypin.  The resultant peptides were analyzed by mass spectrometry and 
proteins were identified based on peptide mass fingerprinting or microsequencing 
combined with bioinformatics.  
Proteins that were identified by peptide mass fingerprinting matched five or more 
peptides.  For microsequencing, at least two sequence tags were typically used for protein 
identification.  For some proteins however, a positive identification was obtained with 
only one sequence tag.  In these cases, a theoretical digest of the protein was performed 
and the experimental mass spectra were manually interpreted to determine if the 
identification could be accepted.  All of the proteins identified in this analysis have a 
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Mascot score that exceeds the 95% confidence level set by the software.  Also, the pI and 
molecular weight of each protein were verified on the 2D-gel image. 
 Most mitochondrial proteins are encoded by the nuclear genome and synthesized 
as precursors in the cytosol.  From here, the precursor proteins are imported into the 
organelle based on targeting sequences that are cleaved once they reach the mitochondria.  
The targeting sequence is not part of a functional mitochondrial protein.  Thus, that part 
of the amino acid sequence does not influence the pI and molecular weight of a given 
protein.  Unfortunately, for some mitochondrial proteins, the amino acid portion of the 
targeting sequence has not yet been determined.  Thus, the pI and molecular weight of 
some proteins, as reported in databases such as SwissProt does not correspond to the 
position of the protein on the 2D-gel map.  
Sample purity was evaluated based on protein identification.  An annotated 2D-
gel image of the crude mitochondrial fraction is shown in Figure 15.  Table 1 lists the 
proteins identified in the crude fraction.  Of the 93 spots that were identified, 48, or 52% 
are currently known to be associated with a cellular compartment other than 
mitochondria.  Thus, only 48% of the proteins identified in the crude fraction are known 
to localize to mitochondria.  Figure 16 shows the annotated proteomic gel map of the 
purified mitochondrial fraction.  Table 2 lists the proteins identified in the purified 
mitochondrial fraction.  In this fraction, we have identified 184 spots, corresponding to 
156 unique protein identifications.  Of these 156 proteins, 132, or 80% are reported to 
belong to the mitochondria, while only 24 of the proteins are not known to be associated 
with the organelle.  Based on these results, we have optimized a method to isolate 
purified mitochondria.       
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Figure 15.  Annotated 2D-gel map of the soluble proteins extracted from the crude 
mitochondrial fraction.
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Spot Accession Number Protein Location
1 P30049 ATP synthase delta chain M
2 P10606 Cytochrome c oxidae polypetide Vb M
3 P02248 Ubiquitin C
4 P02249 Ubiquitin C
5 P14179 Macrophage migration inhibitory factor M
6 Q04837 Single-stranded DNA binding protein M
7 O75947 ATP synthase D chain M
8 Q07021 Complement component 1 M
9 P42655 Mitochondrial import stimulation factor M
10 P35214 14-3-3 protein gamma C
11 P08865 40S ribosomal protein SA R
12 P29692 Elongation factor 1-delta C
13 O60812 Heterogenous nuclear protein c-like N
14 P07910 Heterogenous nuclear protein C1/C2 N
15 P08727 Cytokeratin 19 C
16 P19012 Cytokeratin 15 C
17 P02570 Beta-actin C
18 P05783 Cytokeratin 18 C
19 P04765 Eukaryotic initiation factor 4A-1 C 
20 P05787 Cytokeratin 8 C
21 P31930 Ubiquinol-cyt. C reductase protein 1 M
22 P30101 Disulfide isomerase, ER-60 ER
23 P10809 HSP-60 M
24 Q9BQE3 Tubulin, alpha-6 chain C
25 P05218 Tubulin, beta-5 chain C
26 P06756 ATP synthase beta chain M
27 P05388 60S acidic ribosomal protein P0 R
Table 1.  Proteins identified in the crude mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, 
C-cytosol, ER-enodplasmic reticulum, N-nucleus, L-lysosome, R-ribosome.
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Spot Accession Number Protein Location
28 P07339 Cathepsin D L
29 P35232 Prohibition C
30 P07339 Cathepsin D L
31 P47756 F-actin capping protein beta subunit C
32 Q13162 Peroxiredoxin 4 C
33 P30084 Enoyl-CoA hydratase M
34 P42126 3,2-trans-enoyl CoA isomerase M
35 P30040 ER protein 29 ER
36 P45880 VDAC-2 M 
37 P04792 HSP-27 C
38 P30048 Peroxiredoxin 3 M
39 Q9HAV7 GrpE protein homolog 1 M
40 P47985 Ubiquinol-cyt C reductase iron-sulfur M
41 P49411 Elongation factor Tu M
42 P50897 Palmitoyl-protein thioesterase 1 L
43 O43464 Serine protease HTRA2 M
44 P43897 Elongation factor Tu M
45 Q13011 Delta3,5-delta2,4-dienoyl-CoA isomerase M
46 P04406 Glyceraldehyde 3-phosphate dehydrogenase C
47 P07355 Annexin-2 PM
48 P13804 Electron transfer flavoprotein alpha-subunit, precursor M
49 P45880 VDAC-2 M 
50 P25388 Receptor of activated protein kinase C1 C
51 Q99714 3-hydroxyacyl-CoA dehydrogenaseII ER
52 Q9BSE5 Agmatinase, precursor M
53 Q06830 Peroxiredoxin-1 C 
54 Q16836 Short chain 3-hydroxyacyl-CoA dehydrogenase M
Table 1.  Proteins identified in the crude mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, 
C-cytosol, ER-enodplasmic reticulum, N-nucleus, L-lysosome, R-ribosome.
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Spot Accession Number Protein Location
55 Q16836 Short chain 3-hydroxyacyl-CoA dehydrogenase M
56 P21796 VDAC-1 M 
57 P21796 VDAC-1 M 
58 P22695 Ubiquinol-cyt C reductase protein 2 M
59 P22695 Ubiquinol-cyt C reductase protein 2 M
60 O75390 Citrate synthase M
61 P12532 Creatine kinase M
62 P07954 Fumarate hydratase M
63 P26440 Isovaleryl-CoA dehydrogenase M
64 O96008 TOM-40 homolog M
65 Q15365 Poly(rC)-binding protein 1 N/C
66 P06733 Alpha enolase C
67 P25705 ATP synthase alpha chain M
68 P00367 Glutamate dehydrogenase 1 M
69 O75489 NADH-ubiquinone oxidoreductase 30 kDa subunit M
70 P40926 Malate dehydrogenase M
71 P38117 Electron transfer flavoprotein beta-subunit M
72 P11016 Guanine nucleotide binding protein C
73 P05218 Tubulin beta-5 chain C
74 P30041 Peroxiredoxin 6 C
75 P60174 Trioesphosphate isomerase C
76 P18669 Phosphoglycerate mutase 1 C
77 P55795 Heterogenous nuclear protein H N
78 P30043 Flavin reductase C
79 P17080 GTP-binding nuclear protein RAN N
80 P25705 ATP synthase alpha chain M
81 P30043 Flavin reductase C
Table 1.  Proteins identified in the crude mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, 
C-cytosol, ER-enodplasmic reticulum, N-nucleus, L-lysosome, R-ribosome.
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Spot Accession Number Protein Location
82 P30086 Phosphatidylethanolamine-binding protein C
83 P25705 ATP synthase alpha chain M
84 P49821 NADH-ubiquinone oxidoreductase 51 kDa subunit M
85 P19474 52-kD SS-A/Ro autoantigen C
87 P45880 Voltage dependent selective anion channel protien 2 M
88 P31943 Heterogenous nuclear protein H N
89 O75608 Acyl-protein thioesterase 1 C
90 Q8TDO2 Hepatocarcinoma high-expression protein C
91 Q8WUFO Nit protein 2 M
92 P13639 Elongation factor 2 C
93 Q9P129 Calcium binding transporter M
Table 1.  Proteins identified in the crude mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, 
C-cytosol, ER-enodplasmic reticulum, N-nucleus, L-lysosome, R-ribosome.
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Figure 16.  Annotated 2D-gel map of the soluble proteins extracted from the purified 
mitochondrial fraction.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
1 P30049 ATP synthase, delta chain M 4.53 15019 2
2 P30044 Peroxiredoxin 5 M 6.96 16899 4
3 P82644 28S ribosomal protein S10 M 7.78 22985 2
4 Q04837 Single-stranded DNA binding protein M 8.24 15195 3
5 Q9P0J0 NADH-ubiquinone oxioreductase B16.6 M 8.23 16557 2
6 P23528 Cofilin C/N/M 8.22 18491 2
7 P10606 Cytochrome c oxidase, polypeptide Vb M 6.33 10613 1
8 P52815 60S ribosomal protein L12 M 5.37 16394 3
9 O75947 ATP synthase, D chain M 5.22 18348 4
10 Q9HAV7 GrpE protein homolog 1 M 6.03 21336 3
11 P04179 Superoxide dismutase M 6.86 22204 2
12 Q9H5G0 Hypothetical protein FLJ23469 C 7.66 24082 5
13 P30048 Peroxiredoxin 3 M 5.77 21468 4
14 P04792 Heat shock protein 27 C 5.95 22768 2
15 O75608 Acyl-protein thioesterase 1 C 6.29 24653 2
16 P47985 Ubiquinol-cytochrome c reductase iron-sulfur M 6.3 21616 2
17 P25705 ATP synthase alpha chain M 8.28 55209 2
18 P30042 ES1 protein homolog M 6.63 24016 3
19 Q99714 3-hydroxyacyl-CoA dehydrogenase type II ER 7.66 26906 5
20 O75489 NADH-ubiquinone oxidoreductase 30 M 5.48 26414 2
21 O75431 Metaxin 2 M 5.9 29744 1
22 P30084 Enoyl-CoA hydratase M 5.88 28354 2
23 P42126 3,2 trans-enoyl CoA isomerase M 6 28736 3
24 Q9Y398 CGI-90 protein M 8.57 35693 3
25 O43819 SCO2 protein homolog M 6.41 25138 11
26 Q8N723 Epoxide hydrolase M 9.29 33842 4
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown,            
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
27 Q07021 Complement component 1 M 4.32 23783 1
28 P07339 Cathepsin D L 5.6 37852 3
29 P51970 NADH-ubiquinone 
oxioreductase 19 M 7.93 19961 3
30 P35232 Prohibitin M 5.57 29786 6
31 Q13011 Delta3,5-delta2,4-dienoyl- CoA isomerase M 6.61 35971 4
32 P53701 Cytochrome c-type heme lyase M 6.25 30582 2
33 P43897 Elongation factor Ts M 6.26 30503 4
34 Q9BX68 Histidine triad nucleotide binding protein C 9.2 17151 2
35 Q8WUF0 Nit protein 2 M 6.82 30561 3
36 Q9BSH4 Hypothetical protein UPF0082 U 8.37 32457 3
37 P45880 Voltage anion dependent 
selective channel protein 2 M 6.32 38069 5
38 P13804 Electron transfer flavoprotein, 
alpha subunit M 8.62 35058 3
39 Q16762 Thisulfate sulfurtransferase M 6.83 33277 5
40 P14854 Cytochrome c oxidase, polypeptide VIb M 6.78 10005 3
41 P45880 Voltage anion dependent 
selective channel protein 2 M 6.32 38069 5
42 Q9H7Z7 Hypothetical protein FLJ14038 M 9.22 41917 3
43 P32322 Pyrroline-5-carboxylate 
reductase C 7.18 33354 2
44 P07355 Annexin A2 C 7.56 38449 2
45 P13995
NAD-dependent 
methylenetetrahydrofolate 
dehydrogenase
M 7.34 34137 4
46 Q9NX40 Hypothetical protein FLJ20455 C 7.02 27609 3
48 Q9BYD6 Ribosomal protein L1 M 8.19 34431 3
49 Q9H9J2 39S ribosomal protein L44 M 8.64 37512 4
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
50 P11177 Pyruvate dehydrogenase E1component, beta subunit M 5.38 35890 5
51 Q9H2U2 Inorganic pyrophosphatase M 5.97 34707 3
52 P14618 Pyruvate kinase, isozymes M1/M2 C 7.95 57769 3
53 P82650 28S ribosomal protein S22 M 7.7 41254 7
54 P49411 Elongation factor Tu M 6.31 45045 4
56 P08559 Pyruvate dehydrogenase E1component, alpha subunit M 6.51 40228 2
57 Q9UKU7 Acyl-CoA dehydrogenase family member 8 M 8.12 45040 1
58 Q9H370 PRO1512 M 5.81 34101 3
59 Q9NYK5 39S ribosomal protein L39 M 6.47 34204 2
60 P36551 Coproporphyrinogen III 
oxidase M 7.31 36865 2
61 Q96DV4 Ribosomal protein L38 M 6.2 40731 3
62 O96008 Probable mitochondrial import receptor TOM40 M 6.79 37869 2
63 Q9BS94
Similar to 3-
hydroxisobutyryl-CoA 
hydrolase
M 8.76 37356 2
64 P62937 Peptidyl-prolyl cis-trans isomerase C 8.37 17128 2
65 O95299 NADH-ubiquinone 
oxioreductase 42 M 6.87 37147 2
66 P82663 28S ribosomal protein S10 M 7.78 22985 4
67 P11310 Acyl-CoA dehydrogenase, 
medium chain M 7.02 43642 4
68 P07954 Fumarate hydratase M 6.99 50081 4
69 O00217 NADH-ubiquinone 
oxidoreductase 23 M 5.1 20290 2
70 P40939 Trifunctional enzyme, alpha 
subunit M 8.98 79009 2
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
71 P12532 Creatine kinase M 7.31 43080 4
72 O75390 Citrate synthase M 6.98 49000 3
73 P22695 Ubiquinol-cytochrome c 
reductase protein 2 M 7.74 46784 4
74 P24752 Acetyl-CoA acetyltransferase M 8.16 41386 3
76 P40926 Malate dehydrogenase M 8.54 33000 3
77 P32119 Peroxiredoxin 2 C 5.66 21878 2
78 P21796 Voltage anion dependent 
selective channel protein 1 M 8.63 30623 4
79 Q16836 Short chain 3-hydroxyacyl-CoA dehydrogenase M 8.38 32822 3
80 Q9Y277 Voltage anion dependent 
selective channel protein 3 M 8.85 30639 3
81 P25705 ATP synthase, alpha subunit M 8.28 55209 2
82 P25705 ATP synthase, alpha subunit M 8.28 55209 3
83 P38117 Electron transfer flavoprotein beta-subunit M 8.24 27826 3
84 Q9NX63
Coiled-coil-helix-coiled-coil-
helix domain containing 
protein 3
M 8.48 26136 3
85 Q9UFN0 NipSnap3A protein C 9.21 28449 1
86 Q06830 Peroxiredoxin 1 C 8.27 22096 3
87 P54819 Adenylate kinase isoenzyme 2 M 7.85 26330 3
88 Q16595 Frataxin M 5.59 17235 2
89 Q9BTZ2 Dehydrogenase/reductase SDR member 4 P 7.66 27554 2
90 Q02338 D-beta-hydroxybutyrate dehydrogenase M 8.16 33075 3
91 P08727 Cytoskeltal keratin 19 C 5.04 44079 4
92 P02571 Actin C 5.31 41766 2
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
93 Q96I99 Succinyl-CoA ligase [GDP-forming] beta-chain M 5.17 42564 4
94 P05783 Cytoskeltal keratin 18 C 5.34 47897 2
95 Q9UJZ1 Membrane associated protein SLP-2 N 6.88 38510 4
96 P31930 Ubiquinol-cytochrome-c 
reductase protein I M 5.43 49101 4
97 P05787 Cytoskeltal keratin 8 C 5.52 53510 4
98 P06756 ATP synthase, beta chain M 5 51769 5
99 Q12849 G-rich sequence factor-1 C 5.51 47969 1
100 P07919 Ubiquinol-cytochrome c 
reductase 11 M 4.46 9246 2
101 P38646 Stress-70 protein M 5.44 68759 4
102 Q96IS6 HSP A8 protein fragment M 5.36 64562 2
103 P28331 NADH-ubiquinone 
oxioreductase 75 M 5.36 77053 2
104 Q9P129 Calcium binding transporter, fragment M 5.31 45790 5
105 P43304 Glycerol-3-phosphate dehydrogenase M 6.17 76323 4
106 P04181 Ornithine aminotransferase M 5.72 44808 4
107 P36957 Dihydrolipoamide 
succinyltransferase M 5.89 41349 2
108 P28838 Cytosol aminopeptidase C 6.29 52607 2
109 Q10713 Mitochondrial processing peptidase alpha subunit M 5.88 54646 2
110 O00330 Pyruvate dehydrogenase protein X component M 6.01 48024 3
111 P30837 Aldehyde dehydrogenase X M 6.01 55292 2
112 P09622 Dihydrolipoyl dehydrogenase M 6.35 50147 2
113 P49419 Aldehyde dehydrogenase family 7 member A1 M 6.24 55200 2
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
114 P62937 Peptidyl-prolyl cis-trans isomerase A C 8.37 17128 2
115 P00367 Glutamate dehydrogenase 1 M 6.71 56008 4
116 Q9HCC0 Methylcrotonoyl-CoA 
carboxylase beta chain M 7.57 61294 3
117 Q9H7G2 Hypothetical protein FLJ20920 M 7.5 68081 3
118 Q16134
Electron transfer 
flavoprotein-ubiquinone 
oxidoreductase
M 6.52 64675 3
119 P30038 Delta-1-pyrroline-5-
carboxylate dehydrogenase M 6.96 59034 3
120 P51649 Succinate semialdehyde dehydrogenase M 7.17 52302 2
121 O95831 Apoptosis-inducing factor M 6.86 55699 4
122 P23786 Carnitine O-palmitoyltransferase II M 7.27 71129 4
123 P11413 Glucose-6-phosphate 1-dehydrogenase C 6.76 59096 7
124 P49748 Acyl-CoA dehydrogenase, 
very-long-chain M 7.74 66175 4
125 Q02252 Methylmalonate-
semialdehyde dehydrogenase M 8.01 54388 4
126 P34897 Serine hydroxymethyltransferase M 8.11 52559 3
127 P25705 ATP synthase, alpha subunit M 8.28 55209 6
128 P80404 4-aminobutyrate 
aminotransferase M 7.19 53270 2
129 O00165 HS1-binding protein M 4.99 31621 3
130 P36776 Lon protease homolog M 6.01 106422 3
131 P04264 Cytoskeletal keratin 2 C 8.16 65847 2
132 Q96RP9 Elongation factor G1 M 6.58 83452 2
133 P54886 Delta 1-pyrroline-5-
carboxylate synthetase M 6.66 87248 3
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
134 Q96RQ3 Methylcrotonoyl-CoA 
carboxylase alpha chain M 6.44 75030 2
135 Q9H455 Hypothetical protein FLJ12692 M 8.16 75432 2
136 Q16822 Phosphoenolpyruvate 
carboxykinase M 6.58 67004 5
137 Q99798 Aconitate hydratase M 6.85 82452 2
138 Q12931 Heat shock protein 75 M 8.05 79961 4
139 P43304 Glycerol-3-phosphate dehydrogenase M 6.17 76323 2
140 P49821 NADH-ubiquinone 
oxioreductase 51 M 7.53 48505 3
142 P22570 NADPH:adrenodoxin 
oxidoreductase M 7.11 49967 2
143 P10809 60 kDa heat shock protein M 5.24 57962 5
144 Q86SX6 Glutaredoxin-related protein C14orf87 M 6.28 16618 2
145 gi 4099125 Cytochrome c oxidase 
subunit Via M 6.43 9744 1
146 Q16891 Mitofilin M 6.08 83626 7
148 P11498 Pyruvate carboxylase M 6.14 127339 3
149 Q02218
2-oxoglutarate 
dehydrogenase E1 
component
M 6.24 108880 4
150 gi 56078960 Hypothetical protein DKFZp434K046 U 5.61 35847 3
151 O75380 NADH-ubiquinone 
oxidoreductase 13 M 7.13 10698 1
152 gi 55957569 OTTHUMO00000016217 N 7.82 11902 1
153 Q16718 NADH-ubiquinone 
oxidoreductase 13 kDa-B M 5.76 13319 3
154 Q9Y375 Complex I intermediate-
associated protein 30 M 5.88 35003 2
155 Q92506 Estradiol 17-beta-dehydrogenase 8 M 6.09 26957 4
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Spot Accession Number Protein Location pI MW
Sequence 
Tags
156 P19404 NADH-ubiquinone 
oxidoreductase 24 M 5.71 23760 3
157 gi 18999392 Cytochrome c oxidase 
subunit Va M 6.3 16752 1
158 Q99757 Thioredoxin M 4.88 11867 1
159 Q9Y6N1 Cytochrome c oxidase 
assembly protein COX11 M 9.21 31438 2
160 P42707 130 kDa leucine-rich protein C 5.5 145109 3
161 P45954 Acyl-CoA dehydrogenase, 
short/branched chain M 5.72 43695 3
163 P50213 Isocitrate dehydrogenase, 
alpha subunit M 5.71 36640 3
164 gi 8923001 Hypothetical protein FLJ11342 M 5.84 25886 3
165 Q13405 39S ribosomal protein L49 M 9.47 19186 1
Table 2.  Proteins identified in the purified mitochondrial fraction.  SwissProt accession 
numbers are provided.  Subcellular location abbreviations: M-mitochondria, C-cytosol, 
ER-enodplasmic reticulum, N-nucleus, L-lysosome, P-peroxisome, U-unknown, 
R-ribosome.  The isoelectric point and molecular weight is provided.  The number of 
microsequences used for protein identification is provided as sequence tags.
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Protein abundance profile of the adriamycin/verapamil resistant MCF-7cell line
Comparative densitrometry was used to compare the protein abundance profiles 
between the drug-susceptible MCF-7 cell line and the cell line selected for resistance to 
adriamycin in the presence of verapamil.  Figure 17 shows a 2D-gel map of the soluble 
proteins extracted from the resistant cell line.  Figure 18 shows the results of the 
comparative analysis and Table 3 lists the relative abundance of each protein that has 
been identified.  In Figure 18, proteins that are circled in red show an increase in 
abundance in the resistant cell line, while proteins circled in yellow show a decreased 
abundance.  In the cell line resistant to adriamycin, eleven proteins show an altered 
abundance.  These proteins are listed in Table 4.  Figure 19 shows the 60S ribosomal 
protein L12 as an example of a protein whose abundance does not change.  Conversely, 
Figures 20 and 21 illustrate the appearance of proteins that have altered abundances as 
they show the increased abundance of 3,2 trans-enoyl CoA isomerase and the decrease in 
abundance of GrpE protein, homolog 1, respectively.
62
Figure 17.  2D-gel map of the mitochondrial proteins from the adriamycin resistant 
MCF-7 cell line.
63
Figure 18.  Comparative 2D-gel image analysis of the mitochondrial fraction from drug-
susceptible and adriamycin resistant MCF-7 cells.  Protein spots circled in red show an 
increased abundance in the resistant cell line.  Protein spots circled in yellow show a 
decrease in abundance in the resistant cell line. 
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Drug Susceptible MCF-7 Mitochondrial
Fraction
Adriamycin/verapamil Resistant MCF-7 
Mitochondrial Fraction
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Spot Protein Abundance Level
1 ATP synthase, delta chain 0.58± 0.02
2 Peroxiredoxin 5 0.63±0.06
3 28S ribosomal protein S10 0.77±0.08
4 Single-stranded DNA binding protein 1.07±0.15
5 NADH-ubiquinone oxioreductase B16.6 subunit 0.89±0.07
6 Cofilin 0.69±0.18
7 Cytochrome c oxidase, polypeptide Vb 0.71±0.14
8 60S ribosomal protein L12 1.02±0.03
9 ATP synthase, D chain 0.82±0.09
10 GrpE protein homolog 1 0.41±0.05
11 Superoxide dismutase 1.24±0.04
12 Hypothetical protein FLJ23469 0.39± 0.02
13 Peroxiredoxin 3 0.98±0.12
14 Heat shock protein 27 0.87±0.05
15 Acyl-protein thioesterase 1 1.10±0.02
16 Ubiquinol-cytochrome c reductase iron-sulfur protein 1.05±0.13
17 ATP synthase alpha chain 8.74± 1.17
18 ES1 protein homolog 0.65±0.01
19 3-hydroxyacyl-CoA dehydrogenase type II 0.62±0.11
20 NADH-ubiquinone oxidoreductase 30 kDa subunit 1.23±0.10
21 Metaxin 2 0.89±0.16
22 Enoyl-CoA hydratase 1.03±0.11
23 3,2 trans-enoyl CoA isomerase 2.91± 0.11
24 CGI-90 protein 0.55±0.17
25 SCO2 protein homolog 0.99±0.04
26 Epoxide hydrolase 0.90±0.07
27 Complement component 1 1.10±0.09
28 Cathepsin D 1.63±0.04
29 NADH-ubiquinone oxioreductase 19 kDa subunit 1.07±0.12
30 Prohibitin 0.66±0.29
Table 3.  Relative abundance of proteins from the drug susceptible and adriamycin 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Abundance Level
31 Delta3,5-delta2,4-dienoyl-CoA isomerase 1.57±0.03
32 Cytochrome c-type heme lyase 1.50±0.24
33 Elongation factor Ts 0.41± 0.02
34 Histidine triad nucleotide binding protein 1.37± 0.03
35 Nit protein 2 0.88±0.02
36 Hypothetical protein UPF0082 1.12±0.16
37 Voltage anion dependent selective channel protein 2 1.15±0.01
38 Electron transfer flavoprotein, alpha subunit 1.57±0.03
39 Thisulfate sulfurtransferase 0.78±0.08
40 Cytochrome c oxidase, polypeptide VIb 0.65±0.04
41 Voltage anion dependent selective channel protein 2 0.58±0.07
42 Hypothetical protein FLJ14038 1.47±0.10
43 Pyrroline-5-carboxylate reductase 0.36±0.05
44 Annexin A2 1.24±0.01
45 NAD-dependent methylenetetrahydrofolate dehydrogenase 0.73±0.05
46 Hypothetical protein FLJ20455 1.04±0.22
48 Ribosomal protein L1 0.77±0.11
49 39S ribosomal protein L44 0.79±0.06
50 Pyruvate dehydrogenase E1component, beta subunit 0.55±0.03
51 Inorganic pyrophosphatase 1.25±0.05
52 Pyruvate kinase, isozymes M1/M2 1.11±0.10
53 28S ribosomal protein S22 1.21±0.12
54 Elongation factor Tu 0.86±0.09
56 Pyruvate dehydrogenase E1component, alpha subunit 1.00±0.07
57 Acyl-CoA dehydrogenase family member 8 0.88±0.04
58 PRO1512 1.03±0.07
59 39S ribosomal protein L39 0.54±0.02
60 Coproporphyrinogen III oxidase 3.04±0.19
61 Ribosomal protein L38 1.34±0.03
62 Probable mitochondrial import receptor subunit TOM40 homolog 1.45±0.01
Table 3.  Relative abundance of proteins from the drug susceptible and adriamycin 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Abundance Level
63 Similar to 3-hydroxisobutyryl-CoA hydrolase 1.35±0.04
64 Peptidyl-prolyl cis- trans isomerase A 0.87±0.02
65 NADH-ubiquinone oxioreductase 42 kDa subunit 1.23±0.07
66 28S ribosomal protein S10 1.02±0.08
67 Acyl-CoA dehydrogenase, medium chain specific 1.14±0.11
68 Fumarate hydratase 1.12±0.09
69 NADH-ubiquinone oxidoreductase 23 kDa subunit 1.00±0.01
70 Trifunctional enzyme, alpha subunit 3.27±0.07
71 Creatine kinase 0.81±0.04
72 Citrate synthase 0.97±0.04
73 Ubiquinol-cytochrome c reductase complex core protein 2 0.85±0.05
74 Acetyl-CoA acetyltransferase 0.90±0.11
76 Malate dehydrogenase 1.50±0.10
77 Peroxiredoxin 2 1.50±0.11
78 Voltage anion dependent selective channel protein 1 1.71±0.28
79 Short chain 3-hydroxyacyl-CoA dehydrogenase 1.28±0.24
80 Voltage anion dependent selective channel protein 3 1.06±0.03
81 ATP synthase, alpha subunit 18.68±3.60
82 ATP synthase, alpha subunit 2.31±0.01
83 Electron transfer flavoprotein beta-subunit 1.26±0.03
84 Coiled-coil- helix-coiled-coil- helix domain containing protein 3 1.03±0.18
85 NipSnap3A protein 0.72±0.01
86 Peroxiredoxin 1 1.54±0.02
87 Adenylate kinase isoenzyme 2 2.40±0.08
88 Frataxin 1.73±0.10
89 Dehydrogenase/reductase SDR family member 4 0.72±0.12
90 D-beta-hydroxybutyrate dehydrogenase 1.16±0.21
91 Cytoskeltal keratin 19 0.90±0.08
92 Actin 0.70±0.09
93 Succinyl-CoA ligase [GDP-forming] beta-chain 1.19±0.10
Table 3.  Relative abundance of proteins from the drug susceptible and adriamycin 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Abundance Level
94 Cytoskeltal keratin 18 0.66±0.12
95 Membrane associated protein SLP-2 0.74±0.08
96 Ubiquinol-cytochrome-c reductase complex core protein I 0.98±0.10
97 Cytoskeltal keratin 8 0.96±0.01
98 ATP synthase, beta chain 1.56±0.10
99 G-rich sequence factor-1 1.23±0.02
100 Ubiquinol-cytochrome c reductase complex 11 kDa protein 1.00±0.01
101 Stress-70 protein 0.84±0.14
102 HSP A8 protein fragment 0.52±0.03
103 NADH-ubiquinone oxioreductase 75 kDa subunit 1.22±0.44
104 Calcium binding transporter, fragment 0.96±0.06
105 Glycerol-3-phosphate dehydrogenase 1.23±0.07
106 Ornithine aminotransferase 1.52±0.64
107 Dihydrolipoamide succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 1.15±0.07
108 Cytosol aminopeptidase 1.29±0.41
109 Mitochondrial processing peptidase alpha subunit 1.01±0.03
110 Pyruvate dehydrogenase protein X component 1.39±0.11
111 Aldehyde dehydrogenase X 0.79±0.26
112 Dihydrolipoyl dehydrogenase 1.07±0.08
113 Aldehyde dehydrogenase family 7 member A1 0.80±0.15
114 Peptidyl-prolyl cis- trans isomerase A 0.99±0.10
115 Glutamate dehydrogenase 1 0.96±0.05
116 Methylcrotonoyl-CoA carboxylase beta chain 1.11±0.13
117 Hypothetical protein FLJ20920 1.46±0.07
118 Electron transfer flavoprotein-ubiquinone oxidoreductase 1.22±0.12
119 Delta-1-pyrroline-5-carboxylate dehydrogenase 1.14±0.19
120 Succinate semialdehyde dehydrogenase 1.99±0.07
121 Apoptosis-inducing factor 1.12±0.04
122 Carnitine O-palmitoyltransferase II 0.97±0.05
Table 3.  Relative abundance of proteins from the drug susceptible and adriamycin 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Abundance Level
123 Glucose-6-phosphate 1-dehydrogenase 1.06±0.06
124 Acyl-CoA dehydrogenase, very-long-chain specific 0.66±0.01
125 Methylmalonate-semialdehyde dehydrogenase 1.48±0.37
126 Serine hydroxymethyltransferase 1.02±0.06
127 ATP synthase, alpha subunit 0.75±0.04
128 4-aminobutyrate aminotransferase 1.46±0.13
129 HS1-binding protein 0.63±0.02
130 Lon protease homolog 1.04±0.08
131 Cytoskeletal keratin 2 1.22±0.09
132 Elongation factor G1 0.92±0.05
133 Delta 1-pyrroline-5-carboxylate synthetase 0.88±0.04
134 Methylcrotonoyl-CoA carboxylase alpha chain 0.83±0.18
135 Hypothetical protein FLJ12692 1.05±0.14
136 Phosphoenolpyruvate carboxykinase 1.45±0.35
137 Aconitate hydratase 0.58±0.05
138 Heat shock protein 75 kDa 1.08±0.09
139 Glycerol-3-phosphate dehydrogenase 1.06±0.08
140 NADH-ubiquinone oxioreductase 51 kDa subunit 0.95±0.06
142 NADPH:adrenodoxin oxidoreductase 0.64±0.01
143 60 kDa heat shock protein 1.21±0.20
144 Glutaredoxin-related protein C14orf87 1.36±0.26
145 Cytochrome c oxidase subunit VIa 0.99±0.13
146 Mitofilin 1.00±0.08
148 Pyruvate carboxylase 0.93±0.07
149 2-oxoglutarate dehydrogenase E1 component 0.94±016
150 Hypothetical protein DKFZp434K046 0.74±0.02
151 NADH-ubiquinone oxidoreductase 13 kDa-A subunit 1.14±0.11
152 OTTHUMO00000016217 0.60±0.28
153 NADH-ubiquinone oxidoreductase 13 kDa-B subunit 1.50±0.19
154 Complex I intermediate-associated protein 30 0.96±0.04
Table 3.  Relative abundance of proteins from the drug susceptible and adriamycin 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
69
Spot Protein Abundance Level
155 Estradiol 17-beta-dehydrogenase 8 1.08±0.11
156 NADH-ubiquinone oxidoreductase 24 kDa subunit 0.74±0.15
157 Cytochrome c oxidase subunit Va 1.31±0.29
158 Thioredoxin 2 1.10±0.04
159 Cytochrome c oxidase assembly protein COX11 1.80±0.63
160 130 kDa leucine-rich protein 0.74±0.01
161 Acyl-CoA dehydrogenase, short/branched chain specific 0.77±0.13
163 Isocitrate dehydrogenase, alpha subunit 1.52±0.06
164 Hypothetical protein FLJ11342 1.37±0.17
165 39S ribosomal protein L49 0.85±0.17
Table 3.  Relative abundance of proteins from the drug susceptible and adriamycin 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Number Protein Relative Abundance
1 Similar to ATP synthase alpha chain 8.74±1.17
2 ATP synthase alpha chain 18.68±3.6
3 ATP synthase alpha chain 2.31±0.01
4 3,2 trans-enoyl CoA isomerase 2.91±0.11
5 Trifunctional enzyme alpha subunit 3.27±0.07
6 Coproporphyrinogen III oxidase 3.04±0.19
7 Adenylate kinase isoenzyme 2 2.4±0.08
8 GrpE protein homolog 1 0.41±0.05
9 Hypothetical protein FLJ23496 0.39±0.02
10 Elongation factor Ts 0.41±0.02
11 Cytochrome c oxidase Vb subunit 0.39±0.02
12 Pyrroline-5-carboxylate reductase 0.36±0.05
13 Cofilin 0.29±0.08
Table 4. Proteins with altered abundances in the adriamycin/verapamil resistant MCF-7 
cell line.  Only changes > 2 are considered significant.
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 Figure 19.  Equal abundance of the 60S ribosomal protein L12 between the drug 
susceptible and adriamycin/verapamil resistant MCF-7 cell line.
Drug-susceptible
Adriamycin/verapamil-resistant
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Figure 20.  Increase in abundance of 3,2 trans-enoyl CoA isomerase between the drug 
susceptible and adriamycin resistant MCF-7 cell line.
Adriamycin/verapamil-resistant
Drug-susceptible
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Figure 21.  Decrease in abundance of the GrpE protein homolog 1 between the drug 
susceptible and adriamycin/verapamil resistant MCF-7 cell line.
Drug-susceptible
Adriamycin/verapamil-resistant
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Protein abundance profiles in the MCF-7 cell line resistant to mitoxantrone
Using comparative densitometry, we have identified four proteins that have 
altered abundances in the cell line selected for resistance to mitoxantrone.  Figure 22 
shows a representative 2D-gel image of the soluble proteins extracted from the 
mitoxantrone-resistant cell line.  Figure 23 shows the results of the comparative analysis, 
where proteins that have an increased abundance are circled in red and proteins with a 
decrease in abundance are circled in yellow.  The relative abundance of each protein is 
presented in Table 6.  Table 7 lists the proteins that show alterations in their abundance 
profiles between the drug-susceptible and mitoxantrone resistant cell lines.  Two proteins 
involved in the oxidative phosphorylation, Cytochrome c oxidase subunit Va, and the 
ATP synthase, alpha subunit show an increase in their abundance.  Conversely, two 
proteins not known to be associated with the mitochondria, Annexin A2 and the 
hypothetical protein FLJ20455 show a decrease in their abundance.
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Figure 22.  2D-gel map of the mitochondrial proteins from the mitoxantrone resistant 
MCF-7 cell line. 
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Figure 23.  Comparative 2D-gel image analysis of the mitochondrial fraction from drug-
susceptible and mitoxantrone-resistant MCF-7 cells.  Protein spots circled in red show an 
increased abundance in the resistant cell line.  Protein spots circled in yellow show a 
decrease in abundance in the resistant cell line.  
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Spot Protein Relative Abundance
1 ATP synthase, delta chain 1.55± 0.11
2 Peroxiredoxin 5 1.19±0.04
3 28S ribosomal protein S10 1.99±0.15
4 Single-stranded DNA binding protein 1.09±0.18
5 NADH-ubiquinone oxioreductase B16.6 subunit 1.00±0.02
6 Cofilin 1.21±0.16
7 Cytochrome c oxidase, polypeptide Vb 1.89±0.09
8 60S ribosomal protein L12 1.11±0.09
9 ATP synthase, D chain 1.93±0.10
10 GrpE protein homolog 1 1.41±0.15
11 Superoxide dismutase 1.42±0.12
12 Hypothetical protein FLJ23469 0.71± 0.25
13 Peroxiredoxin 3 1.38±0.12
14 Heat shock protein 27 1.16±0.17
15 Acyl-protein thioesterase 1 0.70±0.02
16 Ubiquinol-cytochrome c reductase iron-sulfur protein 1.44±0.19
17 ATP synthase alpha chain 4.48± 0.55
18 ES1 protein homolog 1.22±0.19
19 3-hydroxyacyl-CoA dehydrogenase type II 1.28±0.18
20 NADH-ubiquinone oxidoreductase 30 kDa subunit 1.09±0.17
21 Metaxin 2 1.07±0.14
22 Enoyl-CoA hydratase 1.45±0.09
23 3,2 trans-enoyl CoA isomerase 1.14± 0.03
24 CGI-90 protein 1.40±0.23
25 SCO2 protein homolog 0.79±0.03
26 Epoxide hydrolase 1.19±0.18
27 Complement component 1 1.23±0.15
28 Cathepsin D 1.05±0.05
29 NADH-ubiquinone oxioreductase 19 kDa subunit 1.38±0.35
30 Prohibitin 1.96±0.20
Table 5.  Relative abundance of proteins from the drug susceptible and mitoxantrone 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Relative Abundance
31 Delta3,5-delta2,4-dienoyl-CoA isomerase 1.27±0.21
32 Cytochrome c-type heme lyase 0.86±0.05
33 Elongation factor Ts 0.58± 0.14
34 Histidine triad nucleotide binding protein 1.52± 0.11
35 Nit protein 2 0.95±0.09
36 Hypothetical protein UPF0082 1.21±0.23
37 Voltage anion dependent selective channel protein 2 1.09±0.27
38 Electron transfer flavoprotein, alpha subunit 0.96±0.12
39 Thisulfate sulfurtransferase 1.33±0.07
40 Cytochrome c oxidase, polypeptide VIb 1.52±0.33
41 Voltage anion dependent selective channel protein 2 1.08±0.09
42 Hypothetical protein FLJ14038 1.72±0.12
43 Pyrroline-5-carboxylate reductase 0.92±0.11
44 Annexin A2 0.33±0.21
45 NAD-dependent methylenetetrahydrofolate dehydrogenase 1.03±0.11
46 Hypothetical protein FLJ20455 0.25±0.05
48 Ribosomal protein L1 1.54±0.29
49 39S ribosomal protein L44 0.57±0.14
50 Pyruvate dehydrogenase E1component, beta subunit 1.17±0.15
51 Inorganic pyrophosphatase 1.64±0.05
52 Pyruvate kinase, isozymes M1/M2 1.24±0.05
53 28S ribosomal protein S22 1.71±0.67
54 Elongation factor Tu 1.04±0.22
56 Pyruvate dehydrogenase E1component, alpha subunit 0.89±0.22
57 Acyl-CoA dehydrogenase family member 8 0.85±0.03
58 PRO1512 1.42±0.16
59 39S ribosomal protein L39 0.61±0.10
60 Coproporphyrinogen III oxidase N/A
61 Ribosomal protein L38 1.45±0.16
62 Probable mitochondrial import receptor subunit TOM40 homolog 0.81±0.19
Table 5.  Relative abundance of proteins from the drug susceptible and mitoxantrone 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Relative Abundance
63 Similar to 3-hydroxisobutyryl-CoA hydrolase 1.18±0.09
64 Peptidyl-prolyl cis-trans isomerase A 1.81±0.10
65 NADH-ubiquinone oxioreductase 42 kDa subunit 0.74±0.17
66 28S ribosomal protein S10 1.31±0.15
67 Acyl-CoA dehydrogenase, medium chain specific 1.30±0.29
68 Fumarate hydratase 1.17±0.22
69 NADH-ubiquinone oxidoreductase 23 kDa subunit 1.62±0.04
70 Trifunctional enzyme, alpha subunit 1.24±0.18
71 Creatine kinase 0.59±0.07
72 Citrate synthase 0.77±0.08
73 Ubiquinol-cytochrome c reductase complex core protein 2 0.93±0.32
74 Acetyl-CoA acetyltransferase 0.70±0.04
76 Malate dehydrogenase 1.57±0.33
77 Peroxiredoxin 2 1.16±0.14
78 Voltage anion dependent selective channel protein 1 1.10±0.31
79 Short chain 3-hydroxyacyl-CoA dehydrogenase 0.97±0.29
80 Voltage anion dependent selective channel protein 3 1.19±0.21
81 ATP synthase, alpha subunit 2.86±0.51
82 ATP synthase, alpha subunit 5.30±0.77
83 Electron transfer flavoprotein beta-subunit 1.14±0.10
84 Coiled-coil- helix-coiled-coil-helix domain containing protein 3 1.13±0.27
85 NipSnap3A protein 1.15±0.45
86 Peroxiredoxin 1 1.58±0.16
87 Adenylate kinase isoenzyme 2 1.59±0.01
88 Frataxin 1.13±0.21
89 Dehydrogenase/reductase SDR family member 4 1.26±0.13
90 D-beta-hydroxybutyrate dehydrogenase 1.06±0.19
91 Cytoskeltal keratin 19 1.45±0.03
92 Actin 0.89±0.09
93 Succinyl-CoA ligase [GDP-forming] beta-chain 1.07±0.10
Table 5.  Relative abundance of proteins from the drug susceptible and mitoxantrone 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Relative Abundance
94 Cytoskeltal keratin 18 1.32±0.13
95 Membrane associated protein SLP-2 1.08±0.04
96 Ubiquinol-cytochrome-c reductase complex core protein I 1.65±0.06
97 Cytoskeltal keratin 8 0.56±0.06
98 ATP synthase, beta chain 0.99±0.11
99 G-rich sequence factor-1 1.58±0.21
100 Ubiquinol-cytochrome c reductase complex 11 kDa protein 0.97±0.05
101 Stress-70 protein 0.86±0.13
102 HSP A8 protein fragment 1.57±0.15
103 NADH-ubiquinone oxioreductase 75 kDa subunit 1.06±0.23
104 Calcium binding transporter, fragment 0.96±0.11
105 Glycerol-3-phosphate dehydrogenase 0.95±0.07
106 Ornithine aminotransferase 1.04±0.22
107 Dihydrolipoamide succinyltransferase component of 2-
oxoglutarate dehydrogenase complex 1.15±0.01
108 Cytosol aminopeptidase 0.99±0.02
109 Mitochondrial processing peptidase alpha subunit 1.37±0.09
110 Pyruvate dehydrogenase protein X component 0.78±0.10
111 Aldehyde dehydrogenase X 1.24±0.08
112 Dihydrolipoyl dehydrogenase 0.67±0.49
113 Aldehyde dehydrogenase family 7 member A1 1.74±0.12
114 Peptidyl-prolyl cis-trans isomerase A 1.89±0.13
115 Glutamate dehydrogenase 1 1.49±0.22
116 Methylcrotonoyl-CoA carboxylase beta chain 0.98±0.16
117 Hypothetical protein FLJ20920 1.30±0.08
118 Electron transfer flavoprotein-ubiquinone oxidoreductase 0.95±0.07
119 Delta-1-pyrroline-5-carboxylate dehydrogenase 1.29±0.01
120 Succinate semialdehyde dehydrogenase 1.70±0.34
121 Apoptosis-inducing factor 1.58±0.42
122 Carnitine O-palmitoyltransferase II 1.04±0.07
Table 5.  Relative abundance of proteins from the drug susceptible and mitoxantrone 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Relative Abundance
123 Glucose-6-phosphate 1-dehydrogenase 1.29±0.25
124 Acyl-CoA dehydrogenase, very-long-chain specific 1.15±0.16
125 Methylmalonate-semialdehyde dehydrogenase 0.86±0.07
126 Serine hydroxymethyltransferase 0.93±0.10
127 ATP synthase, alpha subunit 0.65±0.13
128 4-aminobutyrate aminotransferase 1.33±0.05
129 HS1-binding protein 1.41±0.05
130 Lon protease homolog 0.75±0.09
131 Cytoskeletal keratin 2 0.61±0.14
132 Elongation factor G1 1.05±0.06
133 Delta 1-pyrroline-5-carboxylate synthetase 1.02±0.13
134 Methylcrotonoyl-CoA carboxylase alpha chain 1.42±0.48
135 Hypothetical protein FLJ12692 1.34±0.42
136 Phosphoenolpyruvate carboxykinase 1.09±0.11
137 Aconitate hydratase 1.39±0.06
138 Heat shock protein 75 kDa 1.20±0.29
139 Glycerol-3-phosphate dehydrogenase 1.56±0.44
140 NADH-ubiquinone oxioreductase 51 kDa subunit 1.76±0.19
142 NADPH:adrenodoxin oxidoreductase 0.97±0.08
143 60 kDa heat shock protein 1.08±0.09
144 Glutaredoxin-related protein C14orf87 1.67±0.42
145 Cytochrome c oxidase subunit Via 1.80±0.09
146 Mitofilin 1.08±0.28
148 Pyruvate carboxylase 0.86±0.12
149 2-oxoglutarate dehydrogenase E1 component 1.44±0.27
150 Hypothetical protein DKFZp434K046 1.28±0.26
151 NADH-ubiquinone oxidoreductase 13 kDa-A subunit 1.55±0.29
152 OTTHUMO00000016217 0.58±0.12
153 NADH-ubiquinone oxidoreductase 13 kDa-B subunit 1.03±0.43
154 Complex I intermediate-associated protein 30 115±0.09
Table 5.  Relative abundance of proteins from the drug susceptible and mitoxantrone 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Protein Relative Abundance
156 NADH-ubiquinone oxidoreductase 24 kDa subunit 1.75±0.13
157 Cytochrome c oxidase subunit Va 3.57±1.24
158 Thioredoxin 1.25±0.14
159 Cytochrome c oxidase assembly protein COX11 1.04±0.06
160 130 kDa leucine-rich protein 1.50±0.16
161 Acyl-CoA dehydrogenase, short/branched chain specific 1.40±0.09
163 Isocitrate dehydrogenase, alpha subunit 0.80±0.11
164 Hypothetical protein FLJ11342 1.32±0.03
165 39S ribosomal protein L49 0.88±0.08
Table 5.  Relative abundance of proteins from the drug susceptible and mitoxantrone 
resistant cell lines.  Abundances are based on four cell harvests, two gels each.
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Spot Number Protein Abundance
1 Cytochrome c oxidase subunit Va 3.57±1.24
2 Similar to ATP synthase alpha chain 2.86±0.51
3 ATP synthase alpha chain 4.48±0.55
4 ATP synthase alpha chain 5.30±0.77
5 Annexin A2 0.33±0.21
6 Hypothetical protein FLJ20455 0.25±0.05
Table 6.  Proteins with altered abundances between the mitoxantrone resistant MCF-7 
cell line.  Only changes > 2 are considered significant.
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Chapter 4:  Discussion
Characterization of MCF-7 mitochondria
Mitochondria are not static organelles.  Electron microscopy reveals that the 
appearance of mitochondria differs between cell and tissue types.  Likewise, it has been 
shown that the number of mitochondria in a given cell type can range from a few hundred 
to thousands, and that the copy number of mitochondrial DNA can also vary.87
Furthermore, depending on the energy requirements of a tissue, mitochondria can also 
exhibit alterations in their patterns of substrate utilization and biosynthetic pathways.88
Although these observations show that mitochondria are altered between cell types, little 
information exists on the extent to which mitochondria differ, how the organelle changes 
in response to stress or disease, or the molecular basis for these differences.  
In an attempt to gain more insight into these differences, a recent proteomic study 
was undertaken to compare the mitochondrial profiles between the brain, heart, liver and 
kidney proteins from a mouse.89  From this work it was shown that fifteen to twenty 
percent of mitochondrial proteins differ between the tissue types.  Based on this 
conclusion and the previously mentioned observations, it is apparent that mitochondria 
differ between cell types at the molecular level.  Thus, it is important to characterize the 
MCF-7 mitochondrial proteome.  To do so, a method to extract the soluble protein 
fraction from purified mitochondria has been optimized.  A 2D-gel map has been 
produced, from which protein spots were identified by mass spectrometry.  Following 
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identification, the mitochondrial proteins have been cataloged for use as a reference in 
future work that utilizes mitochondria from MCF-7 cell lines. 
Proteomic annotation of the genome
Several important pieces of information can be deduced when the subcellular 
location of a protein is determined.  First, it aids in the understanding of how an organelle 
functions.  Second, when a novel or uncharacterized protein is identified, its subcellular 
location can provide clues as to the function of that protein.90  Historically, the 
compartmental location of a protein has been proposed by computational or direct 
experimental methods.  These methods can be somewhat limited however.  More 
recently, proteomic strategies that employ subcellular fractionation have allowed for the 
determination of protein locations on a large-scale.  This is not only the most direct 
approach to elucidate location, but it has also allowed for in-depth investigations of 
proteins that previously were not known to be associated with a particular organelle.  One 
exemplary analysis was conducted on the proteome of the nucleolus.  In this study, thirty 
percent of the identified proteins, including heterochromatin protein 1  isoform, were not 
previously known to belong to the nucleolus.91  Similarly, a mitochondrial proteomic 
study was undertaken, in which, of 599 proteins identified, 163 had not been known to be 
associated with the mitochondria.89  After employing several tests and experimental 
analyses, including analysis of targeting sequences and the formation of GST fusions to 
detect protein location, the authors confirmed that 133 or eighty-five percent of the 163 
proteins are located within the mitochondria.  
In an effort to classify the proteins identified in our work, and to elucidate 
whether those proteins that have not been previously associated with the mitochondria, 
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are actually contaminants from other organelles or in fact could also be mitochondrial, we 
have sought to compare our catalog to those reported in other mitochondrial proteomic 
surveys.  This data is summarized in Table 7, where column one lists the proteins 
identified in this study that are classically reported to belong to other organelles, or 
whose location has yet to be defined.  Column two represents the subcellular location to 
which the proteins are currently reported in the SwissProt database.  In columns three and 
four, the proteins were extracted from mitochondria isolated from tissue samples, and 
purified on either a Percoll or metrizamide gradient, respectively.  The proteins in column 
five were obtained from mitochondria derived from a neuroblastoma cell line and 
purified on a metrizamide gradient.89,92,93  While additional mitochondrial proteomic 
analyses have been reported, these papers were chosen to provide a spectrum of 
experimental conditions, including whether the mitochondria were from tissue sample or 
cell lines and the manner in which those mitochondria were purified.  Although part of 
our reference catalog, proteins including the cytokeratins and actin are excluded from this 
table, as they are known to be highly abundant in cells and are accepted as permanent 
contaminants of most organellar fractions.  The results show that several proteins, such as 
dehydrogenase/reductase SDR family member 4, known to be associated with other 
organelles are not present in the proteomic studies chosen for comparison and are likely 
contaminants in our sample.  On the other hand, proteins such as cathepsin D may be 
associated with the mitochondria.  This protein, which is present in our sample and in 
both the study using Percoll and metrizamide purification strategies, is classified as a 
lysosomal protein.  It has been reported however, that cathepsin D is required for Bax 
insertion into the outer mitochondrial membrane, a process that is equired for apoptosis.94
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Proteins 
Identified in 
this Study
Subcellular 
Location as 
Reported by 
SwissProt
From Tissue 
Isolated on 
Percoll
From Tissue 
Isolated with 
Metrizamide
From Cell 
Culture 
Isolated with 
Metrizamide
Acyl-protein 
thioesterase 1 Cytosol Yes Yes No
3hydroxyacyl
CoA 
dehydrogenase
Endoplasmic 
reticulum No Yes Yes
Cathepsin D Lysosome Yes Yes No
Nit protein 2 None Yes No No
Pyrroline-5-
carboxylate 
reductase
Cytosol Yes No Yes
Annexin A2 Cytosol Yes No Yes
NipSnap3A 
protein Cytosol Yes No Yes
Peroxiredoxin 1 Cytosol Yes Yes Yes
Dehydrogenase
/reductase SDR 
family member 
4
Peroxisomal No No No
G-rich 
sequence 
factor-1 
Cytosol No No Yes
Heat shock 
protein A8
Cytosol
Nucleus No No No
130 kDa 
leucine-rich 
protein
Cytosol No Yes Yes
Table 7.  Comparison of mitochondrial protein catalogs.
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More direct experimental evidence has been obtained to show that nit protein 2 is part of 
the mitochondria. Currently, nit protein 2 does not have an organellar classification in 
protein databases such as SwissProt.  Using confocal microscopy to track a GST-fusion 
protein however, it has been shown that nit 2 does in fact localize to mitochondria.89
Finally, pyrroline-5-carboxylate reductase and peroxiredoxin 1 are present in two of the 
three and all three proteomic studies, respectively.  Because the experimental conditions 
of analyses chosen for comparison are not the same, and because these proteins are 
present in most of the studies, it seems possible that these proteins are closely associated 
with the mitochondria in vivo.  It can be speculated that proteomic studies such as these 
will contribute to the reassignment of proteins to organelles other than those to which 
they have historically been assigned.  
Annotation of hypothetical proteins
Upon sequencing of the human genome, it became apparent that approximately 
thirty percent of open reading frames could encode for proteins that have yet to be 
characterized.95  Although such hypothetical proteins have only been predicted based on 
nucleic acid sequence, they account for numerous positive protein identifications in 
proteomic based work and more recently, such proteins have been postulated to play a 
role in diseases such as Down syndrome.96  Specifically, our work shows an altered 
abundance of two such proteins.  Thus, we have sought to determine the subcellular 
location of the hypothetical proteins identified in this study using two Internet based 
programs, Mitopred (http://mitopred.sdsc.edu/) and Psort (http://psort.nibb.ac.jp/).
Mitopred is used exclusively to determine whether a protein is mitochondrial.  
Users can submit either the SwissProt accession number of the protein, or its amino acid 
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sequence.  The program predicts whether the protein is mitochondrial or non-
mitochondrial based on three factors; occurrence patterns of Pfam domains, amino acid 
composition and pI value differences between mitochondrial and non-mitochondrial 
locations.97  Unlike Mitopred, Psort is used to predict the subcellular location of all 
proteins using one criterion, the presence of sorting signals within the amino acid 
sequence.98  Such sorting signals include cleaveable targeting sequences that are often 
found in mitochondrial proteins, as more than 99% are encoded by the nucleus and must 
be transported to the mitochondria based on those sequences.99
The results of this analysis are shown in Table 8.  All proteins identified as 
hypothetical in this study were first evaluated using MitoPred.  If the reported result was 
non-mitochondrial, those protein locations were then predicted using Psort.  As can be 
seen in rows 2 and 7, hypothetical proteins UPF0082 and DKFZp43k046 were predicted 
as non-mitochondrial using MitoPred, but predicted to be mitochondrial using Psort.   
Because Psort uses only one method to calculate location, it is generally accepted that 
MitoPred can predict mitochondrial proteins more reliably.  Thus, we have concluded 
that at this time, it is not possible to classify the subcellular location of these proteins.  
Interestingly, when mitofilin, protein number 146 in Table 2, was first identified, it had 
yet to be characterized and was a hypothetical protein.  Using the MitoPred algorithm, it 
was predicted to be mitochondrial at a confidence level of 69%.  Upon characterization, it 
was demonstrated that mitofilin does localize to mitochondria.100  Therefore, we feel 
certain in the prediction that the hypothetical proteins, FLJ12962 and FLJ11342, which 
have similar confidence levels, are mitochondrial.
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Hypothetical 
Protein
Prediction of Subcellular 
Location Based on MitoPred
Prediction of Subcellular 
Location Based on Psort
FLJ23469 Non-mitochondrial Cytosolic with 76% 
confidence
UPF0082 Non-mitochondrial Mitochondrial with 48% 
confidence
FLJ14038 Mitochondrial with 92% 
confidence Not applied
FLJ20920 Mitochondrial with 92% 
confidence Not applied
FLJ12692 Mitochondrial with 62% 
confidence Not applied
FLJ20455 Non-mitochondrial Nuclear with 70% 
confidence
DKFZp43k046 Non-mitochondrial Mitochondrial with 57% 
confidence
FLJ11342 Mitochondrial with 74% 
confidence Not applied
PRO1512 Mitochondrial with 100% 
confidence Not applied
OTTHUMP000000
16217 Non-mitochondrial
Nuclear with 76% 
confidence
Stomatin like 
protein 2
Mitochondrial with 92% 
confidence Not applied
Table 8.  Predicted subcellular location of hypothetical proteins.  MitoPred and Psort 
prediction algorithms are exploited.
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Biological implications of abundance changes
In this study, we have detected the altered abundance of 15 proteins from the 
MCF-7 cell lines resistant to adriamycin and mitoxantrone.  These proteins, listed in 
Table 9, are involved in a number or mitochondrial pathways.  In an effort to contribute 
to the understanding of drug resistance, we have sought to determine the biological 
implications of these abundance changes.   
Fatty acid oxidation
Fatty acid, or -oxidation is the process whereby fatty acid molecules are broken 
down.  This process is essential for maximum cellular energy yield, as it drives the 
synthesis of ATP.  Short, medium and long chain fatty acids are released from adipose 
cells to the cytosol, where they are linked to coenzyme A (CoA).  The resultant fatty acyl 
CoA molecules are then transported from the cytosol to the mitochondrial matrix via 
carnitine palmitoyl transferase.  Through a series of four reactions in the matrix, each 
fatty acyl CoA molecule is oxidized to form one molecule of acetyl CoA and is shortened 
by 2 carbon atoms.  The process continues as all of the carbon atoms are converted to 
acetyl CoA molecules, which are then fed into the citric acid cycle.  In addition to acetyl 
CoA, each turn of -oxidation also yields one molecule each of NADH and FADH2 that, 
together with the NADH and FADH2 generated from glycolysis and the oxidation of 
acetyl CoA in the citric acid cycle, are used to power ATP synthesis via the electron 
transport chain.  In our work with the adriamycin resistant MCF-7 cell line we detect the 
increased abundance of two key enzymes involved in fatty acid oxidation, 3,2 trans-enoyl 
CoA isomerase and the trifunctional enzyme -subunit.  
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Protein Adriamycin resistantMCF-7 Cell Line
Mitoxantrone resistant 
MCF-7 Cell Line
Similar to ATP synthase alpha 
chain 8.74±1.17 2.86±0.51
ATP synthase alpha chain 18.68±3.6 4.48±0.55
ATP synthase alpha chain 2.31±0.01 5.30±0.77
3,2 trans-enoyl CoA isomerase 2.91±0.11 1.14± 0.03
Trifunctional enzyme alpha 
subunit 3.27±0.07 1.24±0.18
Coproporphyrinogen III oxidase 3.04±0.19 Not determined
Adenylate kinase isoenzyme 2 2.4±0.08 1.59±0.01
Cytochrome c oxidase subunit Va 1.31±0.29 3.57±1.24
GrpE protein homolog 1 0.41±0.05 1.41±0.15
Hypothetical protein FLJ23496 0.39±0.02 0.71± 0.25
Elongation factor Ts 0.41±0.02 0.58± 0.14
Cytochrome c oxidase Vb 
subunit 0.39±0.02 1.89±0.09
Pyrroline-5-carboxylate 
reductase 0.36±0.05 0.92±0.11
Cofilin 0.29±0.08 1.21±0.16
Annexin A2 1.24±0.01 0.33±0.21
Hypothetical protein FLJ20455 1.04±0.22 0.25±0.05
Table 9.  Summary of abundance changes in the drug-resistant MCF-7 cell lines.
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Three, two-trans-enoyl CoA isomerase functions as a homodimer to isomerize 
both 3-cis and 3-trans double bonds into the 2-trans configuration.  For complete 
degradation of a fatty acid molecule, its double bonds and those of its intermediates must 
have a trans-configuration.  Unlike the intermediates produced from saturated fatty acids, 
which always meet this criterion, the double bonds of intermediates from unsaturated 
fatty acids can be in a cis configuration.  Processing of such intermediates requires up to 
three additional enzymatic steps.  The isomerase is fundamental in the conversion of such 
bonds; mice deficient in the enzyme are incapable of -oxidation of unsaturated fatty 
acids.101  An increased abundance of 3,2 trans-enoyl CoA isomerase has been reported in 
breast and colon cancer but what role it plays in the malignant transformation is not 
understood.102
The trifunctional enzyme contains four  and four  subunits to catalyze three 
steps in fatty acid oxidation.  The  subunit plays a role in steps two and three of the 
process, as it harbors the 3-hdroxyacyl-CoA dehyrdrogenase and the enoyl CoA 
hydratase activities.  Individually, the trifunctional enzyme has not been shown to play a 
role in cancer, although alterations in it are responsible for several other diseases.103  
Based on the increased abundance of 3,2 trans-enoyl CoA isomerase and the trifunctional 
enzyme -subunit, we propose that there is an increase in fatty acid oxidation in the cell 
line resistant to adriamycin, as compared to the drug -susceptible cell line.  It is important 
to note however, that we have identified additional enzymes involved in fatty acid 
oxidation that do not have altered abundances.   
Since the mid 1900’s it has been known that cancer cells have an altered 
metabolism, including an increase in glycolysis for the production of ATP.104
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Furthermore, it is now accepted that the increased rate of glycolysis is accompanied by a 
decrease in fatty acid oxidation.33  Consistent with our suggestion of an increase in fatty 
acid oxidation in the resistant cell line, is a recent study, which demonstrates that drug-
susceptible cancer cells do increase the rate of glycolysis, while drug-resistant cancer 
cells revert back to fatty acid oxidation for ATP synthesis.105 
Fatty acid oxidation is more efficient than glycolysis for the production of ATP.  
The former can lead to the production of reactive oxygen species, which can damage the 
newly synthesized DNA of cancer cells.  Such damage can force cells to undergo 
apoptosis, which may explain the need for a decrease in fatty acid oxidation.  Drug-
resistant cancer cells, on the other hand, have evolved mechanisms whereby they can 
repair such damage, or even ignore it, which allows them to use the more efficient fatty 
acid oxidation to sustain ATP synthesis.  It has been suggested that such alterations are a 
typical quality of most drug-resistant cells.  However, we do not see evidence for an 
increase in fatty acid oxidation in the cell line resistant to mitoxantrone.  Taking into 
consideration our results, and the previous work that demonstrated an increase in fatty 
acid oxidation in drug-resistant cancer cells, we offer that the alterations observed in 3,2 
trans-enoyl CoA isomerase and the trifunctional enzyme  subunit are consistent with the 
altered metabolic phenotype of drug-resistant cancer cells, which in turn may work to 
support the drug-resistant phenotype.    
Oxidative phosphorylation
Mitochondria are responsible for generating 80-90% of the cell’s energy needs 
through the process of oxidative phosphorylation.  In this way, ATP production is 
coupled to the transfer of electrons to oxygen along protein complexes in the inner 
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mitochondrial membrane.  The electrons are donated from the reduced coenzymes, 
NADH and FADH2, generated during fatty acid oxidation, glycolysis and the citric acid 
cycle.  In three protein complexes along the way, the transfer of electrons is coupled to 
the uphill movement of protons from the mitochondrial matrix across the inner 
mitochondrial membrane to form a proton concentration gradient.  This movement of 
protons also causes the matrix to become negatively charged with respect to the inner 
membrane space and results in formation of an electric potential.  The proton motive 
force, or energy equivalent of the proton concentration gradient and electric potential, 
powers ATP synthesis when protons from the inner membrane space spontaneously 
travel to the mitochondrial matrix through the ATP synthase complex.   
Oxidative phosphorylation, begins at complex I of the electron transport chain, 
NADH-CoQ reductase.  Here, the reduced coenzyme, NADH, donates a pair of electrons 
to coenzyme Q (CoQ) to form CoQH2.  At complex II, succinate CoQ reductase, FADH2
also donates two electrons to CoQ to form CoQH2.  Reduced coenzyme Q then donates 
electrons, a pair at a time, to the third complex, CoQH2-cytochrome c reductase, where 
the electrons are transferred to cytochrome c through a series of intermediate protein 
acceptors.  The reduced cytochrome c then travels to complex IV, cytochrome c oxidase, 
where it transports the electrons, one at a time until they are ultimately transferred to a 
molecule of oxygen to produce H2O.  At complexes I, III and IV, protons are pumped 
across the inner membrane.  When these protons spontaneously travel back from the 
innermembrane space to the matrix through the ATP synthase complex, energy is 
released to power the synthesis of ATP from ADP and inorganic phosphate.  
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In the cell line resistant to adriamycin, we see a decrease in abundance of 
cytchrome c oxidase subunit Vb, while in the mitoxantrone resistant cell line we see an 
increase in the Va subunit of cytochrome c oxidase.  As seen in Table 9, we have 
identified both subunits in each of the cell lines, but their changes in abundance are not 
consistent.  In addition, we have also identified additional subunits of the cytochrome c 
oxidase complex, however only subunits Va and Vb have altered abundances. 
Cytochrome c oxidase is the fourth protein complex of the electron transport 
chain and is composed of thirteen protein subunits.  Subunits I, II and III are encoded by 
mitochondrial DNA and account for the catalytic activity of the complex.  The function 
of the remaining ten subunits, including Va and Vb, has yet to be elucidated.  It has been 
demonstrated that in breast and prostate cancers, there is an increased abundance of these 
subunits.106,107  In the prostate study, it was also shown that there is an increase in 
abundance of subunit IV and a decrease in the abundance of subunit I.  The authors 
concluded that these alterations support the metabolic shift, as previously described, of 
malignant cells to utilize glycolysis for the production of ATP, as opposed to non-
transformed cells, which make use of oxidative phosphorylation.  As compared to the 
increased abundance of the Vb subunit in the prostate study, we see a decrease in 
abundance of the Vb subunit in the adriamycin resistant cell line.  We believe that this 
result supports the hypothesis that drug resistant cancer cells revert back to the use of 
fatty acid oxidation for ATP synthesis, as compared to glycolysis.  
In another study, it was observed that adriamycin resistant leukemia cell lines 
have a decreased cytochrome c oxidase activity.108  The same authors later showed that 
this decrease likely results from the altered expression of several cytochrome c oxidase 
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subunits.52  It was put forward that these alterations may have been generated initially as a 
result of adriamycin resistance, but once modified, the proteins are likely to confer the 
drug resistant phenotype to cancer cells.  Thus, we suggest that alterations in cytochrome 
c oxidase subunits Va and Vb support the shift in metabolic strategy used by drug 
resistant cancer cells and that this alteration can promote drug-resistance.
In both drug resistant cell lines, as seen in Figure 24, we see a decrease in 
abundance of the full-length ATP synthase -subunit protein, while we see an increased 
abundance in truncated isoforms of this protein.  In addition to these changes, we have 
also detected the altered abundance of two additional subunits of the ATP synthase 
complex, d and , as shown in Table 10.  Although these proteins do not quite meet our 
criteria of a 2-fold change, it may be possible that they are also involved in the 
mechanism of drug-resistance in both the adriamycin and mitoxantrone resistant cell 
lines.  
The ATP synthase complex has two components, F1, which is the catalytic part of 
the complex made up of subunits; , , ,  and  and F0, which contains a, b and c and d 
subunits.  Three subunits each, of  and , alternate to form a ring that sits atop the 
subunit, which fits into the c subunit ring of F0.  When protons move from the 
innermembrane space to the matrix during oxidative phosphorylation, they release their 
energy and travel down the transmembrane channel of F0, comprised of subunits a and b.
This energy powers rotation of the  subunit within the c ring, to drive conformational 
changes in the -subunits so that they can; bind ADP and inorganic phosphate, 
spontaneously produce ATP and finally release it.  
Alterations in the ATP synthase complex have been reported in a number of
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Figure 24. The altered abundance of ATP synthase, -subunit.  Panels A, B and C show 
the decrease in abundance of the full-length protein, as circled in yellow, in the drug-
susceptible, adriamycin/verapamil resistant and mitoxantrone resistant MCF-7 cell lines, 
respectively.  Panels D, E and F show the increase in abundance of the truncated proteins, 
as  highlighted by red arrows in the drug-susceptible, adriamycin/verapamil resistant and 
mitoxantrone resistant MCF-7 cell lines, respectively.  
A B C
D E F
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ATP synthase 
subunit
Relative Abundance in the 
Adriamycin Resistant 
MCF-7 Cell Line
Relative Abundance in the 
Mitoxantrone Rresistant 
MCF-7 Cell Line
Full-length  0.75±0.04 0.65±0.13
Truncated * 9.91±8.20 4.21±1.24
b 1.56±0.10 0.99±0.11
 0.58± 0.02 1.55± 0.11
d 0.82±0.09 1.93±0.10
Table 10.  Relative abundance of ATP synthase subunits in the drug resistant MCF-7 cell 
lines.  * In the comparative analysis, 3 isoforms of the truncated alpha subunit have been 
identified.  The abundance of these isoforms has been averaged.
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cancers.  In liver cancer, it has been shown that there is an overall reduction of ATP 
synthase components.  Similarly, in other cancers, including breast, lung and 
oesophageal, it has been shown that a decreased abundance of the -subunit can be used 
as a marker of tumor progression.109,110  The authors of these studies concluded that the 
alterations supported the fact that tumor cells decrease oxidative phosphorylation for the 
production of ATP and suggested that alterations in the complex may also cause drug 
resistance, as a functional complex is required for apoptosis.111,112
More recently, a proteomic analysis has been conducted to determine if there are 
alterations in protein abundances between a drug-susceptible colon cancer cell line and a 
colon cancer line that is resistant to 5-fluorouacil, a commonly used chemotherapeutic.  
Using 2D-GE and comparative densitometry, it was shown that there is a decrease in 
abundance of the full-length ATP synthase, -subunit.113  Furthermore, the authors found 
that this decrease led to a reduced activity of the ATP synthase complex and that a 
functional ATP synthase complex is required for 5-fluorouacil activity.  Taken together, 
the authors concluded that the down-regulation of ATP synthase directly results in drug 
resistance.  Based on the findings in our work, that there is a decrease in abundance of the 
full length ATP synthase, -subunit protein and an increase in truncations of this protein 
in the cell lines resistant to mitoxantrone and adriamycin, in combination with the results 
described for 5-fluorouacil resistance, we suggest that a decrease in the activity of ATP 
synthase may be one mechanism by which cancer cells become drug-resistant.  Also, we 
propose that this mechanism may be conserved across different classes of 
chemotherapeutic agents, as adriamycin and mitoxantrone are antibiotics and 5-
fluorouacil is an antimetabolite.
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Biosynthesis of heme
The biosynthesis of heme is an important process, as heme is found in a variety of 
proteins including the cytochromes, hemoglobin, and the anti-oxidants catalase and 
peroxidase.  These proteins are involved in a variety of processes required for cellular 
homeostasis and their expression can be regulated by reavailability of heme.114  Heme 
synthesis begins in the mitochondria, where succinyl CoA, generated during the citric 
acid cycle, is converted to -aminolevulinic acid by -aminolevulinic acid synthase.  
Once converted, the metabolite translocates into the cytosol where it undergoes three 
enzyme-catalyzed reactions to yield coproporphyrinogen III.  This product then moves 
back into the mitochondria where it is converted into protoporphyrinogen IX by the 
enzyme, coproporphyrinogen III oxidase.  The synthesis of heme is finally completed by 
another two reactions in the mitochondria.  
 In the cell line resistant to adriamycin, there is an increased abundance of sixth 
enzyme in the pathway, coproporphyrinogen III oxidase.  This enzyme, located in the 
innermembrane space of mitochondria, has already been shown to influence the heme 
content in cells.  Using yeast as the model system, a deficiency in heme was shown to 
induce transcription of the gene encoding coproporphyrinogen III oxidase and in erythoid 
cells, where the need for heme is greatest, transfection of an antisense oligonucleotide to 
the enzyme resulted in a decrease in heme production.115,116  In addition, the 
coproporphyrinogen III step is the rate-limiting step in the synthetic pathway.  Based on 
these reports and our observation of an increase in abundance of coproporphyrinogen III 
oxidase, we conclude that there is an increase in the biosynthesis of heme in the cell line 
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that is resistant to adriamycin.  Furthermore, the increase in heme content allows for the 
conjecture of a novel mechanism of resistance to adriamycin. 
One mode of adriamycins’ toxicity is its ability to generate reactive oxygen 
species.  Specifically, this was demonstrated when transgenic mice were made to 
overexpress the anti-oxidant superoxide dismutase.  Mice that did not overexpress the 
enzyme incurred damage from adriamycin, while the transgenic mice were protected 
from the free radical damage.117  A mitochondrial enzyme, superoxide dismutase, 
converts superoxide free radicals into hydrogen peroxide, which is further degraded into 
water and oxygen by another antioxidant, catalase.   Several reports have shown that 
heme transcriptionally activates the genes that encode for both superoxide dismutase and 
catalase.114  
In untreated breast cancer, the capacity for heme biosynthesis is enhanced 20-
fold.118  Rodents treated with adriamycin show a decrease in cellular heme content.119  In 
our MCF-7 cell line selected for resistance to adriamycin in the presence of verapamil, 
we present evidence for an increase in heme synthesis.  Taking these data into 
consideration we suggest the following mechanism for chemoresistance of adriamycin in 
the presence of verapamil:
A:  In untreated breast cancer cells, there is an increase in heme production.  This 
increase activates production of the anti-oxidants superoxide dismutase and catalase to 
protect the newly formed cancer cells from damage by reactive oxygen species that can 
be generated during a number of cellular processes.  The cancer cells survive.  
B:  In breast cancer cells that are treated with and susceptible to adriamycin, the drug 
targets mitochondria and causes a decrease in heme.  Therefore, the anti-oxidants cannot 
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be activated and the cancer cells are susceptible to damage by reactive oxygen species.  
The cancer cells undergo apoptosis.
C:  In breast cancer cells that are treated with, but resistant to adriamycin, the drug 
stimulates expression of coproporphyrinogen III oxidase which in turn stimulates 
production of heme.  Heme activates the production of superoxide dismutase.  The cancer 
cells evade apoptosis and survive.
Apoptosis
Apoptosis, or programmed cell death is a critical process at it regulates normal 
development.  Alterations in the pathway have been implicated in a number of diseases 
including Alzhemiers, Parkinsons and acquired immune deficiency syndrome.  The 
ability of cells to evade apoptosis also leads to the development of cancer and 
furthermore, it is now recognized that mutations along the pathway contribute to drug 
resistance.16,17  Relative to our interests, mitochondria play a central role in apoptosis.  
Thus, it is not surprising that we have observed changes in abundance of two proteins 
thought to be involved in apoptosis, adenylate kinase isoenzyme 2 and cofilin.
Cells express four isoforms of the 26 kDa, adenylate kinase enzyme.  Adenylate 
kinase 1, 2 and 3, located in the cytosol, mitochondrial innermembrane space and 
mitochondrial matrix, respectively, are essential for cell growth and maintenance and 
thus are ubiquitously expressed at all times.  The expression of isozyme 4, on the other 
hand, is more limited as it appears only in response to the induction of specific pathways 
related to the energy needs of a given cell type.120  In the cell line resistant to adriamycin 
in the presence of verapamil, there is an increase in abundance of adenylate kinase 
isoenzyme 2, which functions to regulate the cellular pool of ADP, as it catalyzes the 
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phosphorylation of AMP to ADP.  In addition to this role, it has also been postulated that 
adenylate kinase 2 may be involved in apoptosis.120
In order for apoptosis to occur, soluble proteins located in the innermembrane 
space of mitochondria, such as cytochrome c and apoptosis inducing factor, must be 
released into the cytosol where they interact with other proteins to form the apoptosome 
complex to initiate the caspase cascade.  Presently, three models have been suggested to 
explain the mechanism by which these proteins are released.  Briefly, these models 
propose that; cyctochrome c is released through specific channels in the outer 
mitochondrial membrane that are opened by the Bcl-2 family of proteins, that 
cytochrome c is released by opening of the permeability transition pore complex that 
spans the inner and outer membranes, and finally that cytochrome c is released through 
mitochondrial rupturing.  Proteomic analyses have shown that adenylate kinase 2 is 
released from the innermembrane space in each case, but whether this release is non-
specific or could potentially play a role in apoptosis could not be determined.  To clarify, 
an elegant study was done in which Jurkat cells were treated with etoposide, a 
chemotherapeutic agent, to induce apoptosis.121  Immunoblot assays that screened for 
cytochrome c and adenylate kinase 2 in the mitochondrial and cytosolic fractions of these 
cells revealed that the two proteins are released from mitochondria into the cytosol 
concomitantly. These results suggest that adenylate kinase 2 is likely to be involved in 
apoptosis, although its role has yet to be elucidated.  Because the isozyme indirectly 
influences cellular levels of ATP, it has been proposed that it may affect energy 
metabolism or the activation of the caspase cascade by the apoptosome complex, a 
process that requires ATP hydrolysis.120  On the other hand, the role of adenylate kinase 2 
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in apoptosis could be different from its normal function.  Until its role in apoptosis is 
elucidated, the altered abundance of adenylate kinase 2 in the resistant cell line cannot be 
explained.
Unlike adenylate kinase 2, which shows an increase in abundance, we observe a 
significant decrease in the abundance of cofilin in the cell line resistant to adriamycin. 
Cofilin is located predominantly in the cytosol of cells where it regulates actin dynamics 
by increasing the rate of actin depolymerization to promote actin turnover.  Also, it is the 
major component of nuclear and cytosolic actin rods.  In addition to this function, it has 
been demonstrated that cofilin plays a major role in apoptosis; upon early induction of the 
pathway, it translocates to the mitochondria to induce massive apoptosis.123  These results 
were demonstrated when mitochondria were isolated from various cancer cells lines and 
induced to undergo apoptosis by treatment with the anti-cancer drugs staurosporine and 
etoposide.123  From this work, it was shown that the translocation of cofilin precedes the 
release of cytochrome c from the innermembrane space of mitochondria, and that 
following translocation, cofilin accumulates in mitochondria.123  Furthermore, it was also 
shown that a reduction in cofilin inhibited the release of cytochrome c and prevented the 
cells from undergoing apoptosis.123  These results suggest that cofilin serves as a pro-
apoptotic protein and that a decrease in its abundance can negatively affect apoptosis.  
Based on this study, and our data, in which we see a decreased abundance of cofilin in 
the mitochondrial fraction from MCF-7 cells resistant to adriamycin, we suggest that 
alterations in the apoptotic pathway, upstream of mitochondria, reduce translocation of 
cofilin from the cytosol to the organelle, which serves to disrupt apotosis and that this is 
one mechanism by which resistance is conferred in this cell line.  
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In the mitoxantrone resistant cell line, we did not observe alterations in proteins 
that are thought to be associated with apoptosis.  Unfortunately, we were not able to 
identify cytochrome c in either the drug-susceptible or drug- resistant cell lines.  This can 
likely be attributed to our isolation procedure, as it has been shown that homogenization 
can cause premature release of cytochrome c from the innermembrane space of 
mitochondria into the cytosol.124  
Mitochondrial homeostasis
In the MCF-7 cell line selected for resistance to adriamycin in the presence of 
verapamil, we see a decrease in abundance of two proteins essential for mitochondrial 
homeostasis, GrpE protein homolog 1 and elongation factor Ts.  Specifically, both 
proteins are involved in maintenance of the mitochondrial proteome.  GrpE1 is involved 
with the import of nuclear encoded mitochondrial proteins, while elongation factor Ts 
plays a role in translation of those proteins that are encoded by the mitochondrial 
genome.
Of the estimated 1200 mitochondrial proteins, only one percent are encoded by 
the mitochondrial genome.  These proteins are extremely important however, as all 
thirteen are part of complexes within the electron transport chain, including the ATP 
synthase complex.  Translation of these proteins requires two factors, elongation factor 
Tu and elongation factor Ts.  Elongation factor Tu interacts with amino-acyl tRNA to 
promote its binding to the active site of mitochondrial ribosomes.  This process requires 
that elongation factor Tu be bound by GTP.  Once binding occurs, GTP is hydrolyzed to
GDP, making elongation factor Tu inactive.  Elongation factor Ts functions to promote 
recycling of the inactive GDP bound form of elongation factor Tu to the active, GTP 
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bound state.125  It follows then, that a decrease in the abundance of elongation factor Ts 
could potentially decrease the rate of protein translation, which in turn could ultimately 
affect the production of ATP as the proteins encoded by mitochondrial DNA are involved 
in oxidative phosphorylation.  In support of this idea, we have identified an additional six 
proteins, listed in Table 11, that show a decrease in abundance and though their decrease 
does not meet our criteria of a 2-fold change, they too are involved in translation of 
proteins encoded by the mitochondrial genome.
In contrast to the mitochondrial genome, nuclear DNA encodes more than ninety-
nine percent of mitochondrial proteins, which must be transported to the organelle for it 
to function properly.  Precursor proteins are translated in the cytosol and then brought 
into the mitochondria, where they are folded and finally shuttled to their proper 
compartments.  Import of the proteins begins when they are bound by one of two 
cytosolic chaperones, cytosolic heat shock protein 70 and mitochondrial-import 
stimulation factor.  These proteins function to keep the nascent proteins in an unfolded 
state and to deliver them to the mitochondria, where they enter the matrix after traveling 
through translocation receptors that span the outer and inner mitochondrial membranes.  
As the proteins enter the matrix, the mitochondrial form of heat shock protein 70 binds 
them, so as to prevent aggregation, precipitation of premature folding.   Heat shock 
protein 70 utilizes the energy released from ATP hydrolysis to improve its substrate 
binding capacity and requires two co-chaperones to function properly, heat shock protein 
40 and GrpE protein. Heat shock protein 40 works to accelerate the rate of ATP 
hydrolysis and strengthen binding of the substrate, while GrpE protein binds to the 
ATPase domain to accelerate release of the precursor proteins from heat shock 
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Protein Relative Abundance Level
28S ribosomal protein S10 0.77±0.08
Ribosomal protein L1 0.77±0.11
39S ribosomal protein L44 0.54±0.01
Elongation factor Tu 0.86±0.09
39S ribosomal protein L39 0.54±0.02
39S ribosomal protein L49 0.67±0.03
Table 11.  Relative abundance of proteins involved in translation machinery in the 
adriamycin resistant MCF-7 cell line.
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protein 70.126 Once released, the proteins are bound to other chaperones for folding, and 
then shuttled to their proper location within the organelle.
A role for chaperone proteins in cancer and apoptosis has been demonstrated. 
Expression of the cytosolic form of heat shock protein 70 is associated with an improved 
prognosis in some types of cancer, while in others, like breast cancer it is associated with 
malignancy.127  Its role in the inhibition of apoptosis has also been elucidated; it prevents 
recruitment of procaspase 9 to the apoptosome complex in the cytosol to hinder initiation 
of the caspase cascade.128   Similarly, heat shock protein 40 can interact with Bax to 
prevent its translocation to mitochondria, a move that is required for the release of 
cytochrome c and other proteins from mitochondria, thereby also preventing apoptosis.129
As of yet, it is not known what, if any role GrpE plays in the progression of cancer or 
apoptosis.  It has been demonstrated that GrpE is essential for import of mitochondrial 
proteins.  Perhaps its decrease represents an impaired rate for the release of mitochondrial 
proteins from heat shock protein 70.  In turn, this could alter translocation of proteins to 
their proper locations within the mitochondria, which may ultimately compromise proper 
functioning of the organelle.   
Proteins not known to be located in mitochondria
We have observed a decrease in abundance of four proteins that are not known to 
belong to the mitochondria in both of the drug-resistant MCF-7 cell lines.  In the cell line 
selected for resistance to adriamycin in the presence of verapamil, we see a decrease in 
pyrroline 5-carboxylate reductase and the hypothetical protein FLJ23469, as shown in 
Table 4.  In the cell line resistant to mitoxantrone, as shown in Table 6, we see a decrease 
in annexin II and the hypothetical protein FLJ20455.  Because these proteins may interact 
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or associate with mitochondria and we see that they have an altered abundance, their role 
in cancer progession and/or resistance will be discussed briefly.
Pyrroline-5-carboxylate reductase is located in the cytosol, where it is involved in 
the final step of proline synthesis; it catalyzes the reduction of pyrroline-5-carboxylate to 
proline.  Proline can then enter the mitochondria where it is oxidized back to pyrroline-5-
carboxylate reductase by the mitochondrial enzyme, proline oxidase.  Literature indicates 
that the interconversion of pyrroline-5-carboxylate and proline results in a metabolic 
shuttle that transfers redox equivalents between the cytosol and mitochondria and reports 
have proposed that proline oxidation in cells that overexpress proline oxidase results in 
the generation of reactive oxygen species due to this metabolic shuttling.130,131  Although 
no such link has been suggested for pyrroline-5-carboxylate reductase, it has been 
reported that the enzyme, along with several others, can be used to distinguish neoplastic 
from nonneoplastic colon cells.132  To date, this protein has not been implicated in cancer 
drug resistance, but the fact that the abundance of pyrroline-5-carboxylate reductase is 
increased in colon cancer and decreased in our cells resistant to adriamycin, signals that it 
could play a role in the switch from drug-susceptible to drug-resistant malignancy.  
Annexin II shows a decreased abundance in the cell line resistant to mitoxantrone.  
The annexin family of proteins contains both calcium and phospholipid binding domains 
in the amino acid sequence.  Annexin II is found in the lamina below the plasma 
membrane where it cross-links plasma membrane phospholipids with actin and the 
cytoskeleton and plays a role in apoptosis.  Others have noted that the abundance of 
annexin II is reduced in prostate cancer as compared to non-transformed prostate cells, 
while its abundance is increased pancreatic cancer cells.133,134  In an MCF-7 breast cancer 
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cell line resistant to 5-fluorouracil, genomic studies showed that there is drug-induced 
expression of the gene encoding annexin II.135  Similar results were provided in a 
proteomic study that demonstrated an increased abundance of annexin I in several 
multidrug-resistant cancer cell lines.136  Collectively, these data indicate that the annexin 
protein family, specifically annexin II, is involved in cancer progression and drug 
resistance.  It is puzzling that in our work we see a decrease in abundance of annexin II, 
while in other resistant cell lines there is an increase of the protein.  In order to determine 
how the altered abundance of this protein contributes to drug resistance, further work 
must be done.
Unfortunately, little information currently exists on the hypothetical proteins that 
we observe to have altered abundances.  The hypothetical protein, FLJ23469, which 
exhibits a reduced abundance in the cell line resistant to adriamycin is predicted, with 
67% confidence, to be a cytosolic protein.  Based on its amino acid sequence, this protein 
is postulated to have a metabolic activity, but what specific pathway it maybe involved in 
has not been elucidated.  In the mitoxantrone resistant cell line, we report a decrease in 
abundance of the hypothetical protein FLJ20455.  Using Psort, this protein is predicted to 
belong to the nucleus.  The results of the sorting analysis are provided in Table 8.  The 
gene encoding this hypothetical protein was recognized during a study aimed at 
identifying novel genes that may be involved an immune response in ovarian cancer.137
Since that time, no further work has been reported in which a protein has been 
characterized, so it can only be speculated that this protein may play an immuno-
responsive role in cancer.
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In the comparative analysis presented in this study, we have identified 15 proteins 
that show altered abundances in the MCF-7 cell lines selected for resistance to 
adriamycin in the presence of verapamil and for mitoxantrone.  Eleven of the proteins 
were detected in the adriamycin-resistant cell line.  These proteins are involved in a 
number of mitochondrial pathways including fatty acid oxidation, oxidative 
phosphorylation and apoptosis.  Based on our observations, we suggest that multiple 
mechanisms can be responsible for the promotion of adriamycin resistance at the 
mitochondrial level.  Conversely, mitochondrial proteins that show altered abundances in 
the mitoxantrone-resistant cell line only play a role in oxidative phosphorylation.  Thus, 
we offer that at the mitochondria, resistance to mitoxantrone can develop through 
alterations in electron transport and oxidative phosphorylation.  
It is important that additional work be done to further investigate the mechanisms 
of drug-resistance conferred by the proteins that show an altered abundance.  For 
example, genetic knockout and overexpression studies should be performed to determine 
if the proteins whose abundances have changed in this study play a role in drug-
resistance.  If so, these proteins may be exploited as biomarkers and/or drug-targets for 
novel chemotherapeutic agents. 
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Summary and proscpectus
The objective of this study was to identify mitochondrial proteins whose 
abundances changed between a drug-susceptible MCF-7 breast cancer cell line and the 
MCF-7 cell lines selected for resistance to adriamycin in the presence of verapamil and to 
mitoxantrone.  It was also our objective to consider how these proteins contribute to drug 
resistance.  We have identified fifteen proteins that show an altered abundance in the two 
drug resistant cell lines.  For some proteins, such as coproporphyrinogen III oxidase, we 
were able to suggest a mechanism by which they contribute to drug-resistance.  On the 
other hand, for proteins such as the ATP synthase, -subunit, we were not able to suggest 
a mechanism.   
In the adriamycin resistant cell line we have detected eleven proteins that show an 
altered abundance.  These proteins are involved in multiple mitochondrial pathways, 
including fatty acid oxidation, apoptosis and oxidative phosphorylation.  In the cell line 
selected for resistance to mitoxantrone, we see the altered abundance of proteins that 
involved solely in oxidative phosphorylation.  Based on these differences, we offer that 
resistance to adriamycin can develop through alterations in multiple mitochondrial 
pathways, while resistance to mitoxantrone, at the mitochondrial level, is the result of 
alterations in oxidative phosphorylation.
In the cell line selected for resistance to adriamycin in the presence of verapamil, 
we see an increase in abundance of the protein coproporphyrinogen III oxidase.  The 
increase of this protein suggests that there is an increase in the heme content of the 
resistant cells.  Because heme can transcriptionally activate proteins that protect cells 
from damage by reactive oxygen species and since one mode of adriamycins toxicity is 
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the production of free radicals, we propose that the resistant cells have altered the 
biosynthesis of heme so that they are protected from the toxic effects of adriamycin.
In both drug resistant cell lines, we see an increase in three truncated isoforms of 
the ATP synthase complex, -subunit.  Accompanying this change we also see a decrease 
in the full-length protein.  Alterations in this and additional subunits of the ATP synthase 
complex have been linked to malignancy and drug resistance.  Unfortunately, we were 
not able to propose a mechanism for how this resistance can be conferred, but we 
hypothesize that alterations in this subunit promote drug resistance and that this 
resistance is likely to be conserved across different classes of chemotherapeutic drugs.
In completion of this project, we have created a proteomic map of MCF-7 
mitochondria, which can be used as a reference in future work that utilizes this cell line. 
In this effort, we have identified about ten percent of the estimated mitochondrial 
proteins.  To increase the coverage of mitochondrial proteins, work is currently being 
done in our lab that utilizes a shotgun approach.  This should allow us to characterize low 
abundance and basic proteins, often neglected and incompatible with gel based work.  
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